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1. Introduction 
1.1 Prevalence and pathogenesis of non-alcoholic fatty liver 
disease  
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in 
industrialized countries with a prevalence of 20–46% [1-5]. NAFLD is 
characterized by an excessive hepatic fat accumulation termed steatosis and is 
defined by the presence of fat accumulation in > 5% of hepatocytes [6]. NAFLD 
represents a spectrum of liver diseases that ranges from simple steatosis to non-
alcoholic steatohepatitis (NASH, chronic liver inflammation) or end-stage liver 
diseases such as cirrhosis and hepatocellular carcinoma (HCC) [6]. The diagnosis 
of NAFLD requires the exclusion of alcohol intake (> 20-30 g/d), drugs (e.g. 
tamoxifen, steroids, estrogens) or genetic diseases, e.g. Wilson disease [6]. 
NAFLD is the liver component of the metabolic syndrome, since obesity, insulin 
resistance, type II diabetes and dyslipidemia are associated with NAFLD [7]. 
Especially in western society, the prevalence of NAFLD reaches up to 70–90% in 
patients with diabetes or obesity [5].  
The underlying molecular mechanisms of a progression from steatosis to more 
severe liver disease stages, e.g. NASH and cirrhosis, remain unclear. However, 
the so called “two-hit” model is widely accepted to explain how steatosis 
progresses towards NASH. In this model, the first hit is an excessive fat 
accumulation in the liver, caused by an increased fat supply, rise in lipolysis [8] of 
the adipose tissue or de novo lipogenesis [9-11] as well as an modified fatty acid 
oxidation [12]. As a second hit, elevated oxidative stress, dysfunctional 
mitochondria [13-15], an altered intestinal microbiome and enhanced intestinal 
permeability leading to inflammation [16-18] have been demonstrated to be 
associated with NAFLD to NASH progression. Therefore, lipid-caused cell death 
(lipotoxicity), mitochondrial dysfunctions and chronic inflammation seem to be of 
special importance as hits in NAFLD progression.  
 
 
Introduction 
P a g e | 2 
1.2 Toxic effects of free fatty acid overload in NAFLD 
The increase in lipolysis and de novo lipogenesis leads to elevated levels of free 
non-esterified fatty acids (NEFA) in the liver and the serum of patients with 
steatosis and NASH [19, 20]. However, whether enhanced NEFA levels are cell-
toxic seem to depend on specific fatty acid species to be increased. Saturated 
fatty acids (SFAs), such as C16:0 (palmitic acid), induce endoplasmic reticulum 
(ER)-stress [21], lysosomal disruption [22, 23], the mitochondrial membrane 
permeability transition (MPT) [22, 24, 25], cytochrome c release from mitochondria 
and apoptosis [24-28] in hepatocytes. In contrast, the monounsaturated fatty 
acid (MUFA) C18:1 (oleic acid) displays no cell-toxic effect but rather enhances 
lipid accumulating properties [25-27] and rescues C16:0-induced toxicity [25, 28-
30]. The essential polyunsaturated fatty acid (PUFA) C18:2 (linoleic acid) is 
metabolized in mammalians to C20:4 (arachidonic acid) [31]. C20:4 is a precursor 
of the pro-inflammatory prostaglandins as well as leucotrienes and C18:2 is 
therefore assumed to enhance inflammation. Controversially, an immune-
suppressive effect has been described for C18:2 as well [32-34]. Additionally, fatty 
acids have been suggested to function as uncoupling agents in mitochondria, 
shuttling protons from the inter membrane space (IMS) into the mitochondrial 
matrix and force membrane potential (MMP) depolarization [35].  
Therefore, lipotoxicity may cause mitochondrial dysfunction. However, almost all of 
these indicated effects have been determined in cell culture (in vitro) or via fatty 
acid supply upon isolated mitochondria. In vivo, the influence of free fatty acid 
overload upon mitochondrial behavior is less understood.  
 
1.3 The mitochondrion as central target in NAFLD 
1.3.1 Mitochondrial structure and function 
Mitochondria produce the main body of cellular energy (ATP) via oxidative 
phosphorylation [36], regulate programmed cell death (apoptosis) [37-39] and 
cellular calcium homeostasis [40, 41]. Mitochondria are an important source of 
reactive oxygen species (ROS) within mammalian cells [39]. Furthermore, 
mitochondria are the key organelles in lipid metabolization as fatty acid ß-oxidation 
takes place within the mitochondrial matrix (Fig. 1). Mitochondria contain an outer 
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membrane (OM), intermembrane space (IMS), inner membrane (IM) and the 
mitochondrial matrix (Fig. 1).  
 
 
 
 
 
 
 
 
 
 
Fig. 1: Schematic illustration of mitochondrial compartmentalization and main functions 
Catabolism of fatty acids (FAs) and carbohydrates takes place in the mitochondrial matrix via  
ß-oxidation or TCA cycle, supplying reduction equivalents for the electron transport chain (CI-CIV). 
During electron transport, protons (H
+
) are pumped via CI, CIII or CIV into the intermembrane 
space (IMS) creating a proton gradient and a negative charge inside the mitochondrion. The 
protons flow back into the matrix across CV, which produces ATP from ADP+Pi. Upon electron 
leakage superoxide anion (O2*
-
) is formed leading to oxidative damage of mitochondrial proteins, 
DNA (mtDNA) or lipids, e.g. cardiolipin (CL). This results, together with high intra-mitochondrial 
calcium levels, in an elevated permeabilization (MPT) of the inner membrane (IM) followed by 
increased permebilization of the outer membrane (MOMP) and the release of IMS proteins, e.g. 
cytochrome c (Cyt. c) as well as the induction of cell death (apoptosis). 
 
The OM delimitates the mitochondrion from the cytosol and is permeable for 
molecules with a size up to 5 kDa [42, 43]. The OM of liver mitochondria consist of 
280–600 µg phospholipids/mg protein as well as 20–60 µg sterols [44]. The main 
phospholipid in the OM of liver mitochondria is phosphatidylcholine (PC) 
containing about 22% C16:0, 25% C18:0 (stearic acid) and 30% C20:4, followed 
by phosphatidylethanolamine (PE) with approximately 12%, 31%, 31% C16:0, 
C18:0, C20:4, respectively [44-46].  
The inner mitochondrial membrane (IM) is folded into cristae (Fig. 1), contains 
almost no sterols, 40% PC, 35% PE and around 21% cardiolipin (CL) [44-46]. CL 
is unique for IM and liver mitochondrial CL consist of > 70% C18:2 [47]. The IM is 
only permeable for gases such as O2 and NH3. To maintain a mitochondrial 
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membrane potential (MMP) of approximately -180 mV, metabolites as well as ions 
have to be transported by channels across the IM [48] (Fig. 1). Massively 
increased calcium-influx may disturb the MMP leading to the membrane 
permeability transition (MPT), followed by increased influx of ions and water into 
the matrix (swelling) [49] and the rupture of the OM (MOMP, Fig. 1).  
An intact IM is especially necessary for mitochondrial energy production. Electrons 
from the reduction equivalents NADH or FADH2 produced by the tricarboxylic 
acid (TCA) cycle are entered into complex I or II and are transported via 
ubiquinone, complex III and Cyt. c to complex IV, consuming oxygen (Fig. 1). 
During electron transport, protons are pumped in the IMS by complex I, III and IV, 
establishing a negative charge inside the mitochondrion (Fig. 1). This gradient is 
used by the ATP synthase (complex V) as protons re-enter the matrix and force 
the formation of ATP from ADP and Pi (Fig. 1). Consequently, due to this coupling 
of the electron transport chain (ETC) with the ATP production, loss of IM-tightness 
results in proton leakage, termed as uncoupling, and lower ATP production. 
Moreover, electron leakage may promote mitochondrial ROS production, lipid 
peroxidation and mitochondrial DNA (mtDNA) damage that may cause increased 
apoptosis (Fig. 1). 
 
1.3.2 Mitochondrial alterations in NAFLD 
Diverse structural and functional impairments of mitochondria have been 
described in NAFLD and NASH. Swollen mega-mitochondria, circular cristae and 
crystalline inclusions have been reported in humans [14, 50-54] as well as in 
animal models [55, 56] with NAFLD. As functional impairments, a reduced ATP 
production capacity [57, 58], an altered respiration [59-61], increased lipid 
peroxidation [13, 14] and augmented ROS production [15, 62, 63] have been 
reported in liver mitochondria from humans and rodents with NAFLD or NASH. 
Despite these results, it is still a matter of debate whether mitochondrial alterations 
are steatosis or NASH-dependent, and if such modifications restore or aggravate 
disease progression. A main reason for this insufficient understanding is caused 
by conflicting results dependent on the diversity of NAFLD animal and feeding 
models. Several of them do not or only partially reflect the human situation and 
therefore complicate the interpretation of these studies.  
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1.4 Animal models to study mitochondrial impairments in 
NAFLD 
Choline-deficient nutrition is frequently used to investigate the molecular 
mechanisms in steatosis and NASH since early liver damage and liver 
inflammation occur upon short term feeding. Choline deficiency induces liver 
steatosis because the choline derivative, phosphatidylcholine (PC), is a main 
constituent of very low density lipoprotein (VLDL) and is required for fat export 
from the liver [64]. However, choline deficiency fails to produce insulin resistance 
and metabolic syndrome, which are important features of human NAFLD [65]. 
Wolf et al. established a choline-deficient high fat diet (CD-HFD) model to combine 
early NAFLD to NASH progression with metabolic changes [56]. In a collaborative 
effort, we studied whether CD-HFD causes mitochondrial impairments in mouse 
livers. Of note, CD-HFD feeding induced steatosis, liver damage and similar 
mitochondrial alterations as observed in humans (ballooned cristae, lower ATP 
production, Fig. 3) [56]. However, if these mitochondrial impairments are caused 
by choline deficiency or by high fat intake or if they are a consequence of liver 
damage, has not been evaluated in this feeding model. More importantly, choline 
deficiency does not mirror human dietary habits and the early and frequent NASH 
development is non-conform to the human situation.  
For these reasons, the human-like “American Lifestyle-induced Obesity 
Syndrome” (ALiOS) model also termed “western diet” (WD) model has been 
chosen in the current thesis to unravel the role of mitochondria upon malnutrition. 
This feeding model was established by Tetri et al. including high concentrations of 
saturated fatty acids (SFAs) in the diet and fructose supplementation in drinking 
water [66]. Thus, the WD model resembles the eating habits in western society. 
Feeding mice this WD demonstrated a phenotype of NAFLD after 16 weeks [66], 
revealed first signs of NASH after 24 weeks and displayed more advanced NASH 
after 48 weeks of feeding [67]. Consequently, the WD feeding animal model 
reflects human NAFLD pathogenesis as a slowly progressive disease.  
With respect to the concept that two or multiple hits are necessary to promote 
steatosis to NASH progression, WD feeding is applied in the present study to LPP 
rats (Wilson disease animal model). Wilson disease is an autosomal recessively 
inherited disorder with loss-of-function mutations in the copper transporter 
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ATP7B [68]. LPP rats contain the same genetic defect in Atp7b. Homozygous 
Atp7b-/- rats, but not heterozygous Atp7b+/- rats, develop mitochondrial copper 
overload, mitochondrial dysfunction and acute liver failure [69, 70]. Additionally, 
patients with Wilson disease often display liver steatosis, chronic liver 
inflammation as well as fibrosis [71] and thus become frequently misdiagnosed as 
NAFLD [72]. Since steatosis as well as Wilson disease target mitochondria, it is 
analyzed whether steatosis-related and copper-related mitochondrial dysfunctions 
are additive and it is examined if WD promotes Wilson disease progression. 
 
1.5 The activated immune system in NAFLD  
In case of obesity and NASH, it has been reported that hepatic macrophages 
(Kupffer cells) and recruited macrophages [73] are activated via  
damage-associated molecular pattern (DAMP) such as soluble ATP, oxidative 
stress or disrupted mitochondria, leading to the induction of the NLRP3 
inflammasome in the liver [74-76] (Fig. 2). The NOD-like pyrin domain containing 
receptor 3 (NLRP3) inflammasome is a multiprotein complex (~700 kDa), which 
consist of NLRP3, ASC adaptor protein (apoptosis-associated speck-like protein 
containing caspase activation and recruitment domain) and pro-caspase-1 [77] 
(Fig. 2). Following inflammasome activation, conformal changes occur and pro-
caspase-1 is auto-activated. The active caspase-1 processes pro-IL-1ß and  
pro-IL-18 to their biological active forms (Fig. 2). These pro-inflammatory cytokines 
are further released into the circulation and induce, among others, the activation of 
NFκB (nuclear factor kappa-light-chain-enhancer of activated B cells), which 
elevates pro-IL-1 and pro-IL-18 transcription [78] (Fig. 2). 
Moreover, during obesity and NASH, the adaptive immune system is activated as 
well via infiltration of pro-inflammatory CD4+T cells, CD8+T cells and B cells  
[79-81] into the adipose tissue paralleled by CD8+T cell infiltration into the liver 
[56]. T lymphocytes are activated by antigen-presenting cells (e.g. dendritic cells, 
DC) and differentiate into CD4+T or CD8+T cells that secrete immune-regulatory 
cytokines or cytotoxic proteins, respectively (Fig. 2). CD4+T cells further activate 
B cells to differentiate into antibody-producing plasma cells and therefore elevate 
the efficiency of the immune response (Fig. 2). In agreement, increased levels of 
pathogenic IgG antibodies are present in obese mice [79]. 
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Fig. 2: Schematic overview of the interplay between innate and adaptive immunity during 
damage recognition 
Damage-associated molecular patterns (DAMPs) are recognized via Toll-like receptors (TLRs) 
upon dendritic cells (DCs) of the innate immune system and activate in combination with K
+
-efflux 
or soluble ATP the NLRP3 inflammasome, leading to caspase-1 activation and the processing of 
mature IL-1ß and IL-18. At this, NFκB regulates the transcription of pro-IL-1ß and pro-IL-18. In the 
lymph node, DCs present MHCII-bound DAMPs to T cells, following T cell differentiation into 
CD4
+
T cells and CD8
+
T cells as well as B cell activation into antibody-producing plasma cells. 
(Adapted from: Famakin et al. 2014 [82]) 
 
In a collaborative effort, we have studied the impact of B and T lymphocytes in 
NAFLD progression by feeding a CD-HFD to Rag1-/- mice [56]. Rag1-/- mice are 
deficient in mature B and T cells [83]. CD-HFD fed Rag1-/- mice did not develop 
any signs of steatosis, liver damage, NASH or liver cancer compared to wildtype 
controls [56]. Furthermore, we revealed that CD-HFD-related mitochondrial 
structural changes (ballooned cristae) and functional impairments, such as 
decreased ATP production and elevated susceptibility to calcium, are absent in 
Rag1-/- mice in contrast to wildtype mice (Fig. 3, unpublished data). Because of the 
observed protective effect, depleting components of the adaptive immune system 
in mitochondrial functionality, the present work addresses the issue if a depletion 
Introduction 
P a g e | 8 
of innate immune system components (NLRP3-/-, IL-18R-/-, IL-1R-/-) avoids 
mitochondrial impairments as well.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3: CD-HFD-induced mitochondrial changes are not present in Rag1
-/-
 mice  
(A) Representative electron micrographs reveal high quota of rounded and widened cristae (arrow) 
in CD-HFD wildtype mitochondria those are not present in CD-HFD mitochondria isolated from 
Rag1
-/-
 mice (scale bar: 1 µm). (B) Mitochondrial ATP production decreases upon CD-HFD and is 
re-established in Rag1
-/-
 mice. (C) Earlier depolarization of the MMP occurs in wildtype CD-HFD 
mitochondria treated with 100 µM calcium and this is delayed in Rag1
-/-
 mitochondria.  
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1.6 Aim of the study 
The prevalence of NAFLD is steadily rising in industrialized countries over the last 
decades. The molecular mechanisms that cause steatosis to NASH progression 
remain incompletely understood and therapeutic strategies are mostly lacking. 
Consequently, NASH-related cirrhosis is the third most common cause of liver 
transplantation worldwide [6]. Lipid overflow, mitochondrial dysfunction and  
low-grade chronic inflammation are important hallmarks of NASH but whether and 
how they influence the NAFLD to NASH progression is still a matter of debate. 
Therefore, the present thesis addresses the issues whether mitochondrial 
impairments are steatosis-related or appear as consequence of liver damage in 
NASH. Thus, C57BL/6 mice were fed a western diet (WD) for 6 to 48 weeks. The 
molecular mechanisms that cause the mitochondrial changes are characterized 
and it is studied if the depletion of the NLRP3 inflammasome (NLRP3-/-, IL-18R-/-, 
IL-1R-/-) prevent mitochondrial dysfunction.  
Since steatosis and mitochondrial impairments occur in Wilson disease, the impact 
of WD in Wilson disease progression is analyzed to examine if steatosis- and 
Wilson disease-related mitochondrial deficits are additive and aggravate disease 
progression. 
Finally, the impact of single fatty acids on hepatocyte viability and mitochondrial 
functionality is investigated to unravel the molecular mechanisms that cause 
steatosis and mitochondrial impairments upon WD nutrition. 
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2. Material and Methods 
2.1 Reagents and technical equipment 
 
Tab. 1: Chemicals, dyes and cell culture reagents 
Name Producer  
37 component FAME mix Supelco, Sigma-Aldrich, Taufkirchen, Germany 
Acetone Merck, Darmstadt, Germany 
ADP (adenosine-5’-diphosphate)  Sigma-Aldrich, Taufkirchen, Germany 
Albumin Fraction V, (BSA, fatty acid free)  Carl Roth, Karlsruhe, Germany  
6-Aminocabronic acid Carl Roth, Karlsruhe, Germany 
Amplex
TM
 Red Molecular Probes, Invitrogen, Karlsruhe, 
Germany 
Antibiotic-antimycotic solution Life Technologies, Darmstadt, Germany 
Antimycin A Sigma-Aldrich, Taufkirchen, Germany 
Arachidonic aicd (C20:4) Sigma-Aldrich, Taufkirchen, Germany 
ATP (adenosine-5’-triphosphate disodium salt) Roche Diagnostics, Mannheim, Germany 
ATP Bioluminescence Assay Kit  
(luciferase reagent, ATP standard, cell lysis 
reagent, dilution buffer) 
Roche Diagnostics, Mannheim, Germany  
CaCl2 (calcium chloride)  Carl Roth, Karlsruhe, Germany 
CAY-10566 (SCD1 inhibitor) Cayman Chemical Company, Ann Arbor, MI, 
USA 
CCCP (Carbonyl cyanide m-chloro-phenyl-
hydrazone)  
Sigma-Aldrich, Taufkirchen, Germany 
Chloroform Sigma-Aldrich, Taufkirchen, Germany 
Coomassie® Brilliant Blue G-250 Serva Electrophoresis GmbH, Heidelberg, 
Germany 
CuCl2*2H2O (copper (II) chloride-dihydrate)  Sigma-Aldrich, Taufkirchen, Germany 
Cyclosporine A (CysA)  Fluka, Sigma-Aldrich, Taufkirchen, Germany 
Derivatization reagent Supelco, Sigma-Aldrich, Taufkirchen, Germany 
Digitonin (high purity) Calbiochem, Sigma-Aldrich, Taufkirchen, 
Germany 
DiOC6 (3,3'-dihexyloxacarbocyanine iodide) Molecular Probes, Invitrogen, Karlsruhe, 
Germany 
DMSO (dimethylsulfoxide)  Sigma-Aldrich, Taufkirchen, Germany 
DPBS (Dulbecco’s phosphate buffered saline) Biochrom AG, Berlin, Germany 
DPH (1,6-diphenyl-1,3,5-hexatriene)  Sigma-Aldrich, Taufkirchen, Germany 
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Name Producer  
DTNB (5’5-dithiobis-2-nitrobenzoic acid) Sigma-Aldrich, Taufkirchen, Germany 
EGTA (ethylene glycol-bis(2-amino-ethylether)- 
tetraacetic acid)  
Fluka, Sigma-Aldrich, Taufkirchen, Germany 
Ethanol  Merck, Darmstadt, Germany 
FCCP (Carbonyl cyanide-p-trifluoromethoxy-
phenylhydrazone)  
Sigma-Aldrich, Taufkirchen, Germany 
FCS (fetal calf serum) Biochrom AG, Berlin, Germany 
Glucose Sigma-Aldrich, Taufkirchen, Germany 
Glutamate (monohydrate) Fluka, Sigma-Aldrich, Taufkirchen, Germany 
Glycerin  Sigma-Aldrich, Taufkirchen, Germany 
Glycine Sigma-Aldrich, Taufkirchen, Germany 
HEPES (4-(2-hydroxyethyl)piperazine-1-
ethanesulfonic acid)  
Sigma-Aldrich, Taufkirchen, Germany 
Hexane Merck, Darmstadt, Germany 
Hoechst 33342  Life Technologies, Darmstadt, Germany 
Imidazole Carl Roth, Karlsruhe, Germany 
KCl (potassium chloride)  Merck, Darmstadt, Germany 
KCN (potassium ferrocyanide * 3H2O) Sigma-Aldrich, Taufkirchen, Germany 
KOH (potassium hydroxide)  Merck, Darmstadt, Germany 
Linoleic acid (C18:2) Sigma-Aldrich, Taufkirchen, Germany 
20x LumiGLO
®
 reagent and 20x peroxide  Cell Signaling Technology, Frankfurt a.M., 
Germany 
MgCl2 (magnesium chloride)  Sigma-Aldrich, Taufkirchen, Germany 
Methanol  Fluka, Sigma-Aldrich, Taufkirchen, Germany 
3-MA (3-methyladenine) Sigma-Aldrich, Taufkirchen, Germany 
Malate (disodium salt) Merck, Darmstadt, Germany 
Mitosox
TM
 Red Molecular Probes, Invitrogen, Karlsruhe, 
Germany 
MOPS (4-morpholinepropanesulfonic acid)  Fluka, Sigma-Aldrich, Taufkirchen, Germany 
NaCl (sodium chloride)  Sigma-Aldrich, Taufkirchen, Germany 
NaOH (sodium hydroxide solution)  Fluka, Sigma-Aldrich, Taufkirchen, Germany 
NEAA (non-essential amino acids) Life Technologies, Darmstadt, Germany 
Neutral red  Sigma-Aldrich, Taufkirchen, Germany  
Nile Red Sigma-Aldrich, Taufkirchen, Germany 
NP40 (Tergitol-type nonyl phenoxypolyethoxyl-
ethanol) 
Sigma-Aldrich, Taufkirchen, Germany 
Oleic acid (C18:1) Sigma-Aldrich, Taufkirchen, Germany 
Oligomycin Sigma-Aldrich, Taufkirchen, Germany 
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Name Producer  
  
Palmitic acid (C16:0) Sigma-Aldrich, Taufkirchen, Germany 
Palmitoylcarnitine-DL-chloride Sigma-Aldrich, Taufkirchen, Germany 
Percoll®  GE Healthcare, Munich, Germany 
Phosphoric acid (H3PO4) Sigma-Aldrich, Taufkirchen, Germany 
Rh123 (Rhodamine 123)  Invitrogen, Karlsruhe, Germany  
Rotenone  Sigma-Aldrich, Taufkirchen, Germany 
SDS (sodium salt) Serva Electrophoresis GmbH, Heidelberg, 
Germany 
Sodium pyruvate Life Technologies, Darmstadt, Germany 
Stearic acid (C18:0) Sigma-Aldrich, Taufkirchen, Germany 
Succinate Na2-salt * 6H2O  Sigma-Aldrich, Taufkirchen, Germany 
Sucrose  Fluka, Sigma-Aldrich, Taufkirchen, Germany 
THF (tetrahydrofurane)  Carl Roth, Karlsruhe, Germany  
TMA-DPH (Trimethylamine-diphenylhexatriene)  Sigma-Aldrich, Taufkirchen, Germany 
Tricine Carl Roth, Karlsruhe, Germany 
TRIS  VWR International GmbH, Ismaning, Germany  
Triton X-100  Sigma-Aldrich, Taufkirchen, Germany 
Trizma
®
 base Sigma-Aldrich, Taufkirchen, Germany 
 
Tab. 2: Technical Equipment 
Name Application Producer  
BD LSRII flow cytometer DiOC6 and Mitosox staining BD Bioscience, Heidelberg, 
Germany 
Centro LB 960 
luminometer 
Luminescence measurement 
(ATP assays) 
Berthold Technologies GmbH & 
Co. KG, Bad Wildbad, Germany 
ChemoCam Imager 3.2 Immunoblotting INTAS Science Imaging 
Instruments GmbH, Göttingen, 
Germany 
Clario-Star plate reader  Fluorescence measurement 
(Hoechst staining) 
BMG Labtech, Ortenberg, 
Germany 
Evos FL Fluorescence 
Microscope  
Microscopy (Nile Red staining) Life Technologies, Darmstadt, 
Germany 
Gas chromatograph 
 
BPX70 GC 
capillary column  
Analyses of mitochondrial fatty 
acid composition 
Separation of fatty acid methyl- 
esters (FAME)  
Carlo ERBA instruments HRGC 
5300, Egelsbach, Germany 
SGE Analytical Science, Milton 
Keynes, United Kingdom 
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Name Application Producer  
Oxygraph-2k  Respiration measurements Oroboros Instruments GmbH, 
Innsbruck, Austria 
   
Respons® 910  Serum transaminases and 
triglyceride measurements 
Diasys Greiner GmbH, Flacht, 
Germany 
 
Synergy 2 plate reader  Fluorescence, anisotropy and 
absorbance measurements 
 
BioTek Instruments, Inc., 
Bad Friedrichshall, Germany 
96-well plates (white, flat 
bottom) 
ATP assays Thermo Fisher Scientific GmbH, 
Dreieich, Germany 
 
96-well plates (black, 
clear flat bottom)  
mitochondrial membrane 
potential, swelling, anisotropy, 
H2O2 production 
 
Greiner Bio-One GmbH, 
Frickenhausen, Germany 
96-well plates (clear, flat 
bottom)  
Neutral red, Nile Red, Hoechst 
staining, F1FO-activity   
Falcon, VWR, Ismaning, 
Germany 
 
 
2.2 Animal studies 
Male C57BL/6 wildtype, IL-1R-/- and IL-18R-/- mice were from Charles River 
(Sulzfeld, Germany) and NLRP3-/- mice were kindly provided by the group of 
Prof. M. Schnurr (Department of Clinical Pharmacology, LMU Munich). Mice were 
housed according to the guidelines for the care and use of laboratory animals at 
the University Hospital Munich. Mice had free access to water and food and the 
feeding study started at the age of eight weeks. Standard rodent diet (ND) was 
from Ssniff (Spezialdiäten GmbH, Germany, V1535-0) and western diet (WD) was 
from Altromin (Spezialfutter GmbH & Co. KG, Seelenkamp, Germany). The WD 
was composed of 45% calories from fat and was supplemented with fructose-rich 
water (23.1 g/l fructose, 18.9 g/l glucose-monohydrate) according to the “American 
Lifestyle-induced Obesity Syndrome” (ALiOS) model [66]. 
To study Wilson disease progression upon high caloric nutrition, LPP rats [84] 
(Atp7b-/- or Atp7b+/-) were fed with either WD and fructose-rich water or normal diet 
(Altromin Spezialfutter GmbH & Co. KG, Germany, 1314) and tap water ad libitum. 
The feeding period took 3-5 weeks starting at the age of 46 days and fructose-rich 
water was additionally supplemented with 8.32 mg/l CuCl2*2H2O to adapt 
nutritional copper content to normal diet (13 mg/kg). Rats were maintained under 
the guidelines for the care and use of laboratory animals of the Helmholtz Center 
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Munich. The animal experiments were approved by the government authorities of 
the “Regierung von Oberbayern” (Munich, Germany). 
 
2.3 Serum-, triglyceride- and liver histology analyses 
The serum transaminases (ALT, AST) were analyzed with Respons® 910 
according to the manufactural guideline. R. Wimmer (Department of Medicine II, 
LMU, Munich) did the quantification of liver triglycerides (TGs). 100 mg/ml liver 
tissue was sonicated in 5% NP40 solution, heated for 5 min at 96 °C and cooled 
down on ice. Subsequently, the homogenate was centrifuged for 2 min at 
20,000 g, the supernatant was diluted 1:10 in 5% NP40 solution and analyzed with 
Respons® 910. Histological analyses of hematoxylin and eosin (HE)-stained 
mouse liver samples were done by Prof. D. Mayr (Institute of Pathology, LMU, 
Munich). 
 
2.4 Cell culture experiments  
2.4.1 HepG2 cell cultivation and fatty acid treatment 
HepG2 cells (ATCC, Wesel, Germany) were maintained in 5% CO2 atmosphere at 
37 °C and cultured in minimum essential medium (MEM), containing 1.9 mM 
GlutaMAXTM, 5.5 mM glucose, 10% FCS, 1% non-essential amino acids (NEAA), 
1% sodium pyruvate and 1% antibiotic-antimycotic solution. 
For fatty acid (FA) treatment, cells were cultured 24 h or 48 h with the indicated 
FAs (C16:0, C18:0, C18:1, C18:2, C20:4) or FA-mixtures (SLFC: standard liver 
fatty acid composition, HFLC: high fat liver composition (Fig. 21), containing 
1% bovine serum albumin (BSA, FA-free) as vehicle and diluted in medium with 
2% FCS. The FAs stock solutions (10 mM) were prepared by saponification with 
25 mM KOH at 70 °C. Subsequently, the FAs were complexed (1:1) for 10 min at 
50 °C with BSA (20% dissolved in DPBS), cooled to room temperature (RT) and 
added to HepG2 cells 24 h after seeding. 
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2.4.2 Determination of intracellular lipid accumulation  
Nile Red staining was done as described earlier [85], with slight adaptions. Per 
well of a clear bottom 96-well plate, 2x104 HepG2 cells were seeded and 24 h 
after seeding, the cells were incubated with FAs for 24 h or 48 h. Nile Red was 
freshly diluted 1:200 in DPBS from stock solution (0.5 mg/ml dissolved in acetone) 
and 100 µl were added to each well. After 2 h incubation in the dark at 37 °C, 
Nile Red was removed and cells were washed twice with DPBS. The fat content 
per well was quantified by fluorescence measurements (λEx. 520/25 nm, 
λEm. 620/40 nm) in a plate reader (Synergy 2) or pictured via Evos FL fluorescence 
microscope. To exclude a lower lipid accumulation because of potential cell death, 
the fluorescence intensity of Nile Red staining was normalized to the fluorescence 
intensity of Hoechst staining (nuclear staining, equivalent to cell density). For cell 
density measurement, a 10 mg/ml stock solution of Hoechst dye was diluted 
1:10,000 in DPBS and 100 µl were added to each well. After 50 min incubation in 
the dark at 37 °C, each well was washed twice with DPBS and fluorescence was 
determined with Clario-Star Reader (λEx. 355/20 nm, λEm. 455/30 nm). 
 
2.4.3 Cell viability assay 
For analyzing cell viability, 2x104 HepG2 cells were seeded per well of a clear 
bottom 96-well plate and 24 h after seeding, the cells were incubated with FAs for 
24 h or 48 h. To block SCD1, the cells were incubated with 15 µM CAY-10566 and 
inhibition of autophagy was done by adding 89.3 µM 3-methyladenine (3-MA). 
Neutral red cell toxicity assay was done as described elsewhere [86]. Neutral red 
fluorescence was analyzed after washing and cell de-staining in a plate reader 
(Synergy 2, λEx. 520/25 nm, λEm. 620/40 nm).  
 
2.4.4 Cellular ATP content  
The ATP content of HepG2 cells was measured with the ATP Bioluminescence 
Assay Kit according to the manufactural guidelines. In detail, 1x105 cells were 
pelleted at 400 g for 5 min, dissolved in 100 µl dilution buffer and lysed by adding 
100 µl lysis buffer for 5–10 min at RT. Subsequently, cell lysates were heated for 
5 min at 95 °C, centrifuged for 2 min at 16,000 rcf and the supernatants were 
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diluted 1:5 in dilution buffer. Per well of a 96-well plate (white, flat bottom), 50 µl 
diluted supernatant as well as 50 µl luciferase reagent were added and 
chemiluminescence signals were detected in a luminometer (Centro LB 960). The 
quantification of the ATP content was done via ATP standard curves 
(0, 0.165, 1.65, 16.5, 165, 1650 nM; stock: 16.5 mM). 
 
2.4.5 Oxygen consumption measurements in HepG2 cells 
High-resolution respirometry (HRR) was done in a Oxygraph-2k instrument in 
accordance to an earlier report [87]. Per chamber, 2x106 HepG2 cells were 
supplied in cell culture media containing 2% FCS and oxygen consumption rates 
were measured without any additions (= routine respiration, Fig. 4). To analyze the 
leak respiration, 2.5 mM oligomycin was added (final 2.5 µM). Oligomycin blocks 
the ATP synthase. Therefore, mitochondrial O2 consumption is minimal and is 
equivalent to the unspecific proton leakage across the inner mitochondrial 
membrane (Fig. 4).  
 
 
 
 
 
 
 
 
 
 
Fig. 4: Schematic overview of a high resolution respirometry measurement 
The O2 flux of intact cells per volt (red line) decreases upon oligomycin addition (leak state), 
appears maximal after CCCP application (ETS) and drops down if the respiratory chain 
complexes I+III are blocked via rotenone or antimycin A, respectively. Therefore, the 
O2 concentration in the chamber (blue line) decreases at routine state and much more pronounced 
during ETS but displays almost no reduction at leak state or if CI and CIII are blocked. 
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capacity, Fig. 4). The oxygen flux was baseline-corrected for non-mitochondrial 
O2 consumption with 0.5 µM rotenone (inhibitor of complex I) and 2.5 µM 
antimycin A (inhibitor of complex III, Fig. 4). 
 
2.4.6 Flow cytometry 
Mitochondrial membrane potential (MMP) of HepG2 cells was determined by 
DiOC6 staining and mitochondrial superoxide production was investigated via 
MitosoxTM Red staining according to manufactural guidelines. HepG2 cells (2x106) 
were incubated for 15–20 min at 37 °C with 100 µl buffer, containing 10 mM 
HEPES, 140 mM NaCl, 5 mM CaCl2 and 20 nM DiOC6 or 5 µM Mitosox, 
respectively. After the addition of 100 µl buffer, the stained cells were analyzed by 
flow cytometry (BD LSRII) at λEm. 530 nm or λEm. 585 nm, respectively. As  
MMP-dissipating control, 500 µM CCCP was added. The quantitative evaluations 
of DiOC6-positive cells as well as the amount of HepG2 cells with strong Mitosox 
accumulation were done with FlowJo 7.6.5 software (Tree Star). 
 
2.5 Mitochondrial analyses  
2.5.1 Mitochondrial isolation procedure and adaptation for fatty acid treated 
cells 
Mitochondria were freshly prepared from mouse livers as described elsewhere  
[88-91]. The mitochondria were pelleted by a differential centrifugation and purified 
using Percoll™ density gradient.  
For fatty acid treated HepG2 cells (48 h), the mitochondrial isolation procedure 
was adapted based on protocols reported for cell culture [90, 92] and for white 
adipose tissue [93]. 7–10x106 cells/ml were homogenized via PCC pumping [92] 
with a constant rate of 1400 µl/min. Subsequently, the homogenates from control 
treated cells were cleared through 800 g centrifugation (10 min, 4 °C) and 
mitochondria were pelleted via a 9,000 g centrifugation step (10 min, 4 °C). 
Mitochondria from fatty acid treated cells (48 h) had a lower specific weight and 
did not pellet with the standard isolation procedure. Therefore, homogenates were 
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cleared by 2,000 g centrifugation (10 min, 4 °C) and mitochondria were pelleted by 
20,000 g (10 min, 4 °C).  
 
2.5.2 Mitochondrial swelling and membrane potential measurements 
Mitochondrial swelling (± 50–100 µM calcium) was analyzed in a black 96-well 
plate (clear flat bottom) by light scattering at 540 nm (plate reader Synergy 2). In 
parallel, the mitochondrial membrane potential (MMP) was measured by 
Rhodamine123 (Rh123) fluorescence quenching at λEx. 485/20 nm and 
λEm. 528/20 nm as described elsewhere [88]. The ratio of ± FCCP addition (1 µM), 
was considered as indicative of an intact inner mitochondrial membrane. The 
characterization of the MMP depolarization process was done with MATLAB 
software (CurveAnalyst) as described by Schulz et al. [88] and start, end, 
maximum as well as the duration of the depolarization process (in min) were 
calculated. 
 
2.5.3 ATP production of isolated mitochondria 
The ATP production was measured with the ATP Bioluminescence Assay Kit 
according to the manufactural guideline. Isolated mitochondria (10 µg) were 
incubated with 160 µM ADP and 5 mM succinate for 30 min at RT in a buffer 
containing 0.2 M sucrose, 10 mM MOPS-Tris, 1 mM Pi, 10 µM EGTA, 5 mM 
succinate, 2 µM rotenone. As background control, 2 mM KCN was added that 
blocks respiratory chain (complex IV) and mitochondrial ATP production was 
calculated in pmol/min/mg protein based on background-corrected luminescence 
signals and the ATP standard curves (0, 0.165, 1.65, 16.5, 165, 1650 nM; stock: 
16.5 mM). 
 
2.5.4 F1FO-activity assay 
F1FO-activity (ATP synthase activity) was performed as described before [94, 95]. 
Briefly, 20 µg mitochondria were incubated in buffer containing either 50 mM TRIS 
(pH 8.0) or additional 3 µM oligomycin (F1Fo inhibitor, negative control) for 5 min at 
37 °C in a plate reader (Synergy 2). To start the reaction, a mixture of finally 
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0.5 mM ATP, 3 µM CCCP, 1 mg/ml BSA, 1 µM antimycin A, 10 mM KCl, 4 mM 
MgCl2, 0.2 mM NADH, 2 mM phosphoenolpyruvate (PEP), 4 units of lactate 
dehydrogenase (LDH) and pyruvate kinase (PK) were added (Tab. 3).  
 
Tab. 3: Enzymes and substrates for F1FO-activity measurements 
Enzymes Provider dissolved in final 
concentration 
LDH (lactate dehydrogenase) Roche 50 mM TRIS (pH 8) 4 units/well 
NADH (nicotinamide adenine dinucleotide) Roche 50 mM TRIS (pH 8) 0.2 mM 
PEP (phosphoenolpyruvate) Roche  50 mM TRIS (pH 8) 2 mM 
PK (pyruvate kinase) Roche 50 mM TRIS (pH 8) 4 units/well 
 
The F1FO-activity was determined in the reverse direction following ATP hydrolysis 
and NADH oxidation in parallel to the conversion of pyruvate to lactate (Fig. 5). 
The decrease in NADH absorbance at 340 nm is proportional to the ATPase 
activity and was calculated in nmol/min/mg using the formula: 
(∆A * V)/(ε * h * m)*1000 (∆A: changes in absorbance; V: volume per well; ε: molar 
extinction coefficient of NADH; h: layer thickness, m: content of mitochondria). The 
F1FO-activity was normalized to the activity of the housekeeping enzyme citrate 
synthase. For analyzing the citrate synthase activity, 20 µg mitochondria were 
used and the increase in absorbance of 5-thio-2-nitrobenzoate anion (TNB2-) was 
followed at 412 nm according to the protocols described elsewhere [90, 96]. 
 
  ATP  ATPase    ADP+Pi 
  ADP+Pi + PEP  
PK   ATP + pyruvate 
  pyruvate + NADH+H+ LDH    lactate + NAD+   
Fig. 5: Reaction scheme of the F1FO-activity assay 
F1FO-activity is determined in reverse direction by ATP hydrolysis (ATPase). The reaction is 
coupled with the conversion of phosphoenolpyruvate (PEP) to pyruvate by pyruvate kinase (PK) 
and the conversion of pyruvate and NADH+H
+
 to lactate and NAD
+
 by lactate dehydrogenase 
(LDH). The decrease in NADH is followed spectrophotometrically and is proportional to the F1FO-
activity.  
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2.5.5 Mitochondrial H2O2 production 
According to earlier reports [97], mitochondrial H2O2 production was analyzed 
following Resorufin fluorescence (converted from AmplexTM Red) at λEx. 540/20 nm 
and λEm. 620/40 nm. Substrates were either 10 mM succinate and 2 µM rotenone 
or 5 mM glutamate and 5 mM malate or 10 µM palmitoylcarnitine-DL-chloride and 
2 mM malate in the presence or absence of 3.2 mM ADP.  
 
2.5.6 Fluorescence anisotropy measurements 
Fluorescence anisotropy was determined in DPH- and TMA-DPH-dyed 
mitochondria [98, 99]. Mitochondria (3 µg/µl) were incubated in the dark for 30 min 
at 37 °C with DPH (50 µM dissolved in THF) or TMA-DPH (20 µM dissolved in 
DMSO). Subsequently, 75 µg stained mitochondria were added into a 96-well 
plate (black, clear flat bottom) containing 175 µl buffer (0.2 M sucrose, 10 mM 
MOPS-Tris, 1 mM Pi, 10 µM EGTA, 5 mM succinate, 2 µM rotenone). Parallel (I║) 
and perpendicular (I┴) fluorescence was assessed (Synergy 2, λEx. 366 nm, 
λEm. 425 nm) and fluorescence anisotropy was calculated by Gen5 software 
(BioTek Instruments) using the formula:  
A = (I║ – G * I┴)/(I║ + 2*G * I┴); G = 0.89 [100]. 
 
2.5.7 Structural analysis of isolated mitochondria  
Mitochondrial structure was analyzed via electron microscopy by Dr. B. Popper 
(Biomedical Center, Department of Anatomy and Cell Biology, LMU, Munich) and 
the sample preparation was done by C. Eberhagen and C. Leitzinger (Institute of 
Molecular Toxicology and Pharmacology, Helmholtz Center Munich) as described 
elsewhere [101]. For structural analysis, mitochondria were grouped into “normal 
structured” of the so called “condensed type mitochondria” [102] or in “altered” 
mitochondria with widened cristae and massive matrix condensations. For each 
feeding time point, about 500-700 mitochondria (150-180 mitochondria per animal) 
were included into this analysis. 
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2.5.8 Proteome data analysis 
The analysis of the mitochondrial proteome was done on isolated mitochondria 
from 6–24 weeks fed C57BL/6 mice. Sample digestion and mass spectrometry 
was done by Dr. C. von Törne (Research Unit Protein Science, Helmholtz Center 
Munich) as described elsewhere [103-105]. Data analysis was performed 
comparing ND and WD peptides in an age-matched manner and set as enriched 
or decreased if the mean raw abundance as well as the normalized abundance 
was ≥ 1.5 or ≤ 0.67 in WD compared to ND mitochondrial fractions, respectively. 
Additionally, peptides were set as regulated if the mean differs significantly 
(p < 0.05) between ND and WD and if the coefficient of variation was < 33% 
(Supplementary Table). Using the protein and pathway databases UniProt [106], 
KEGG (Kanehisa Laboratories, Japanese) [107] and PANTHER [108], the 
identified proteins were grouped based to their cellular localization and metabolic 
pathway affiliation. A cluster analysis with Scaffold 4 software (Proteome 
Software, Inc, Portland, OR, USA) revealed a highly comparable proteome with an 
overlap of about 400 proteins (Fig. 6A) and the identified proteins displayed mainly 
mitochondrial origin (Fig. 6B). 
 
 
 
 
 
 
 
 
 
Fig. 6: Quality control of the proteome analysis 
(A) ND and WD mitochondria from mice at different feeding times appear with highly comparable 
proteomes. (B) The isolated fractions mainly contain proteins that are localized in mitochondria. 
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2.5.9 Mitochondrial copper content 
The determination of mitochondrial copper was done by P. Grill (Research Unit 
Analytical BioGeoChemistry, Helmholtz Center Munich) via ICP-OES (Ciros 
Vision, SPECTRO Analytical Instruments GmbH) after wet ashing of samples with 
65% nitric acid [70]. 
 
2.6 Blue Native Page and Immunoblotting  
2.6.1 Blue Native Page 
Mitochondrial protein quantification was done by the Bradford assay [109] and the 
Blue Native Page was performed according to Wittig et al. [110] and Diaz et al. 
[111]. Briefly, 70 µg mitochondrial protein was solubilized in 70 µl buffer (50 mM 
NaCl, 50 mM imidazole, 2 mM 6-aminocabronic acid, 1 mM EDTA, pH 7.0), 
containing digitonin (protein/digitonin ratio 1:6), for 10 min on ice and centrifuged 
at 20,000 g for 20 min. The supernatant was collected and glycerin (final 5%) as 
well as Coomassie® Brilliant Blue G-250 solution (digitonin/dye ratio 1:8; dissolved 
in Bis-Tris buffer, pH 7.0 and 500 mM 6-aminocapronic acid) were added. 15 µg 
protein was loaded on a 3-12% Bis-Tris gel (Invitrogen, Karlsruhe, Germany). Blue 
native gel electrophoresis was done in anode buffer (25 mM imidazole, pH 7.0) 
and blue cathode buffer (50 mM tricine, 7.5 mM imidazole, 0.02% Coomassie) for 
1 h at 150 V and 4 °C. After the exchange of the blue cathode buffer with 1:10 
diluted blue cathode buffer, separation was continued for 1 h at 250 V. For protein 
transfer, gels were de-stained via 30–40 min shaking in transfer buffer (20 mM 
Trizma® base, 150 mM glycine, 20% methanol, 0.05% SDS). 
 
2.6.2 Immunoblotting 
For immunoblotting, separated proteins were transferred from the de-stained  
Bis-Tris gel or SDS-PAGE to an activated PVDF membrane (Bio-Rad, Munich, 
Germany) according to earlier reports [111, 112]. Subsequently, the membranes 
were probed with primary antibodies at 4 °C (overnight) and secondary antibodies 
at 4 °C for 1–2 h (Tab. 4). The detection of specific proteins was achieved by using 
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the 20x LumiGLO® and 20x peroxide reagents. The quantification of the 
chemiluminescence signals was done with ImageJ software [113].  
 
Tab. 4: Primary and secondary antibodies used for immunoblotting 
Primary antibodies Secondary antibodies 
Antigen Provider Dilution Name Provider Dilution 
CS Novus 
Biologicals 
 
1:1000 goat anti-rabbit IgG 
HRP 
Cell Signaling 
Technology 
1:1000 
COXIV Cell Signaling 
Technology 
1:1000 goat anti-rabbit IgG 
HRP 
Cell Signaling 
Technology 
1:1000 
NDUFB8 Abcam 1:2000 goat anti-mouse IgG 
HRP 
Cell Signaling 
Technology 
1:1000 
SCD1 Cell Signaling 
Technology 
1:1000 goat anti-rabbit IgG 
HRP 
Cell Signaling 
Technology 
1:1000 
SDHA Abcam 1:2000 goat anti-rabbit IgG 
HRP 
Cell Signaling 
Technology 
1:1000 
UQCRC2 Abcam 1:500 goat anti-rabbit IgG 
HRP 
Cell Signaling 
Technology 
1:1000 
 
2.7 Quantitative fatty acid analysis by gas chromatography  
Fatty acids (FAs) were extracted from isolated liver mitochondria according to the 
method from Folch with chloroform/methanol (2:1 v/v) [114]. For FA extraction, 
250 µg purified mitochondria were mixed with 4 ml chloroform/methanol. 
Subsequently, the extract was separated from protein debris by centrifugation 
(15 min, 3,500 g) and was washed once with NaCl (0.9%, 0.2-fold volume) and 
twice with methanol/water (1:1 v/v). Afterwards the organic phase was evaporated 
via N2, esterified with derivatization reagent and re-solved in n-hexane 
(hexane/water, 1:1). Fatty acid methyl esters (FAME) were separated by capillary 
gas chromatography at an oven temperature of 120–210°C (steadily increase of 
2 °C/min) and H2 as carrier gas. The detection was done via flame ionization and 
FAMEs were identified by comparison of their retention time relative to those of the 
standard mixture (37 component FAME mix). The quantification was done using 
C15:0 as internal standard by Clarity Lite software (DataApex). Analyzing the fatty 
acid composition of ND and WD chow was done by R. Artmann (Department of 
Medicine II, LMU, Munich). 
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2.8 Statistics 
Data are presented as mean and standard deviation (SD). Statistical analysis was 
performed using Student’s t test and data were tested unpaired and tow-tailed. For 
multiple comparisons, one-way ANOVA and Tukey test was done for parametric 
data or Kruskal-Wallis test for non-parametric data with GraphPad Prism 7 
(GraphPad Software). Differences were considered statistically significant if 
* p < 0.05, ** p < 0.01, *** p < 0.001. 
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3. Results 
3.1 Western diet causes liver steatosis and mitochondrial 
impairments in mice 
3.1.1 Western diet promotes obesity and steatosis 
Nutrition in western society is characterized by an elevated uptake of fat and 
fructose-rich soft drinks, leading to a massive rise of NAFLD-affected persons. In 
order to mirror eating habits, male C57BL/6 mice were fed for 6, 12 and 24 weeks 
with western diet (WD) as well as fructose-containing water and indicators of 
obesity, steatosis and liver damage were determined. Obesity was analyzed by 
the elevation of body weight (Fig. 7A), liver weight (Fig. 7B) and visceral fat mass 
(Fig. 7C). Steatosis was demonstrated by liver triglyceride (TG) accumulation 
(Fig. 7D).  
 
 
 
 
 
 
 
 
 
Fig. 7: Western diet induces obesity and liver steatosis 
(A-D) Body weight (A), liver weight (B), mass of visceral fat (C) and liver TG content (D) of 6, 12 
and 24 weeks fed male C57BL/6 mice are increased in WD compared to ND control (A-C: 6 wk: 
n=8, 12 wk: n=7, 24 wk n=8; D n=4). *Significant to age-matched control. 
 
Histological analyses of the livers demonstrated that WD nutrition induced 
macrosteatosis starting at 12 weeks of feeding, which was more pronounced after 
24 weeks of feeding (Fig. 8). However, signs of liver damage such as apoptosis, 
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necrosis or infiltration of inflammatory cells were not detectable in WD livers 
(Fig. 8). Nevertheless, the liver damage marker ALT was slightly increased in 
serum of 24 weeks fed WD mice (Fig. 14). Thus, WD nutrition caused steatosis 
without establishing NASH in 24 weeks fed mice, which is in parallel with the 
observation in humans that steatosis only slowly aggravates in a minority of 
NAFLD patients.  
 
 
 
 
 
 
 
 
Fig. 8: Liver histology reveals macrosteatosis after 24 weeks of WD feeding 
Hematoxylin/Eosin staining (HE, magnification: 200) of ND and WD mouse liver tissues 
demonstrate macrosteatosis (arrow) after 12 and 24 weeks of WD feeding.  
 
3.1.2 Western diet induces structural alterations in mitochondria 
In human NAFLD and NASH, mitochondrial structural changes have been 
frequently reported [14, 50-54]. However, at which disease stage these 
mitochondrial alterations occur and their role in steatosis progression are still a 
matter of debate. Therefore, liver mitochondria were isolated after 6, 12 and 
24 weeks of feeding and ND as well as WD mitochondrial structures were 
compared by electron microscopy. Structural changes such as rounded and 
ballooned or tubular cristae appeared early after 6 weeks of feeding in WD 
compared to ND mitochondria (Fig. 9A). A quantitative analysis revealed a 
significant higher quota of mitochondria with altered cristae structures after 
6 weeks of feeding in WD (24%) compared to ND (14%) mitochondria (Fig. 9B). 
6 weeks 12 weeks 24 weeks 
ND 
WD 
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The amount of altered mitochondria progressively rose with prolonged feeding 
time and was higher in WD (34%, 39%) than in ND (18%, 29%) mitochondria 
(Fig. 9B). Thus, WD induced similar circular and rounded cristae alterations as 
observed in human NASH [14, 52]. These alterations appeared in parallel to 
steatosis and not as a result of liver damage. 
 
 
 
 
 
 
Fig. 9: Western diet impairs mitochondrial 
structure  
(A) Representative electron micrographs 
demonstrate WD-induced increase in 
mitochondria with rounded and ballooned 
(arrow) or tubular (asterisk) cristae (scale bar: 
1 µm).  
(B) Quantification of altered mitochondria with 
widened and tubular cristae (6/12 wk: n=4; 
24 wk: n=6, 150-180 mitochondria per animal). 
 
3.1.3 Western diet induces minor proteome changes 
The proteome of WD mitochondrial fractions were compared to age-matched ND 
mitochondrial fractions. Only 2–6% (11-37 proteins) of all identified proteins (569) 
were either enriched (≥ 1.5-fold) or reduced (≤ 0.67-fold) in WD compared to ND 
A 
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mitochondrial fractions (Tab. 5). The most consistent alterations were changes in 
lipid metabolism (Tab. 5, Supplementary Table). In detail, proteins involved in lipid 
degradation, ß-oxidation, lipid transport and lipid synthesis were upregulated in 
WD mitochondria. Furthermore, a reduction of lysosomal degradation proteins and 
an elevation of proteins involved in translation processes occurred over time. 
Proteins that are involved in ER stress were increased after 6 weeks of feeding. 
Unexpectedly, proteins that cause lipid synthesis were enriched in WD compared 
to ND mitochondria. Therefore, these proteins underwent a more detailed 
investigation. The FA-modifying enzymes TECR (Trans-2,3-enoyl-CoA reductase), 
ELOVL2 (elongation of very long chain fatty acids) and SCD1 (Stearoyl-
CoA desaturase 1) were increased in WD mitochondria (Tab. 5). TECR and 
ELOVL2 elongate FAs and SCD1 incorporates a double bound at position delta-9. 
SCD1 mainly processes palmitic acid (C16:0) and stearic acid (C18:0) towards 
their monounsaturated counterparts palmitoleic aicd (C16:1n9) and oleic acid 
(C18:1n9), respectively. The upregulation of SCD1 was confirmed by 
immunoblotting and displayed a significant elevation after 6 weeks of feeding 
(Fig. 10). 
 
Fig. 10: Immunoblot analysis of Stearoyl-
CoA desaturase 1 (SCD1)  
(A) Immunoblots from mitochondria isolated 
after 6 weeks feeding reveal upregulation of 
SCD1 in WD. (B) Quantitative evaluation of 
SCD1 expression normalized to citrate 
synthase (CS, n=4). *Significant to age-
matched control. 
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Tab. 5: Comparative proteomic analysis of WD versus ND mitochondrial fractions 
Proteins that are enriched (≥ 1.5-fold) or reduced (≤ 0.67-fold) in WD compared to ND 
mitochondrial fractions are termed as up- or downregulated, respectively. These regulated proteins 
are grouped regarding their biological function and represent 2–6% of all identified proteins. Protein 
description and localization are shown in “Supplementary Table” (page XI). 
WD vs. ND 
fold    
enrichment 
6 wk 12 wk 24 wk 
oxidative > 1.5 ATP5D MT-CO3 MT-ND5, NDUFA11 
phosphorylation < 0.67  MT-ND4, UQCR11   
lipid degradation     
(ß-oxidation)    
> 1.5 ACOT13, HADHB ECHS1, ECI2 ACOT2, CYP2D9, 
EHHADH, HADHA  
< 0.67 ACOX2, LIPA, PHYH  LIPA, PHYH 
lipid transport > 1.5 MTTP, SLC27A5  MCAT SCP2 
lipid synthesis > 1.5 ELOVL2, HMGCS2, 
TECR 
 ECHDC2,ELOVL2, 
HMGCS2, SCD1 
ER stress > 1.5 CALR, CANX, 
HSP90B1, HSPA5, 
P4HB, PDIA6  
  
lysosomal-/ 
protein 
degradation 
> 1.5 
< 0.67 
OTUB1 
CTSB, LGMN,  
LIPA, TPP1  
CTSB, GAA,  
GM2A, SCPEP1  
PMPCA, CTSB, GAA, 
LIPA, FBXO16, 
SCPEP1 
autophagy/ 
apoptosis 
> 1.5 PGRMC1, PEX14  DAP3 NIT1 
< 0.67 CREG1, NIT1 BNIP3, CREG1, 
PEX14 
 
antioxidative > 1.5 SOD1  P4HB 
< 0.67 GPX1 GSTA3, GSTM1, 
GSTZ1 
 
steroid 
metabolism 
> 1.5 CYP2A12  CYP2D9, UGT2B36 
< 0.67 DHRS1 CYP3A16, DHRS1 ALDH1B1, CYP3A16 
translation > 1.5 EEF1A1, GM10036, 
GM5619, MRPL10, 
MRPL43, MRPS23, 
RPLP0, RPLP2, RPS3 
RPL26, RPL9 GM10036, MRPS30, 
RPL9 
< 0.67  MRRF, RNASET2B  
retinol metabolism > 1.5   UGT2B36, STRA6 
< 0.67 STRA6 CYP2A5, STRA6, 
TTR, CYP3A17  
CYP2A5, CYP3A16 
amino acid 
metabolism 
> 1.5 BHMT, FMO5, 
HADHB 
 AMT, EHHADH, HADHA  
< 0.67 ETHE1, NAGS FMO1, GNMT, NAGS, 
QDPR 
ETHE1, GNMT, SARDH 
miscellaneous > 1.5 ALDOB, METTL7A1, 
RPN2, SURF4, 
TMEM205, UGT1A1, 
VKORC1 
FMC1, H2-Q10, 
HSPE1, SELO 
ATL2, BDH1, MCU, 
MTHFS, NNT, SURF4, 
SSR4 
< 0.67 MCU ATL2, ISCU, 
PTGES2, TMEM256 
MUP10, OCT 
identified proteins  
(569) 
up 
down 
37 (6.5%) 
15 (2.6%) 
11 (1.9%) 
28 (4.9%) 
26 (4.6%) 
15 (2.6%) 
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3.1.4 Western diet causes membrane-lipid alterations 
The upregulation of FA-modifying enzymes indicated changes in the FA 
composition of the mitochondrial membranes as a possible reason for WD-related 
cristae modifications (3.1.3). Therefore, the fatty acid profile of mitochondria was 
determined by gas chromatography.  
The gas chromatographic analysis of FAs from isolated mitochondria revealed no 
change in the saturated fatty acid (SFA) content but demonstrated a significant 
rise of monounsaturated fatty acids (MUFAs) in WD compared to ND 
mitochondria. For instance, C16:1 and C18:1 were elevated after 12 and 24 weeks 
of feeding (Tab. 7). Furthermore, the amount of polyunsaturated fatty acids 
(PUFAs) significantly decreased in WD mitochondria (Tab. 7). Although, the ratio 
of unsaturated to saturated FA did not differ between ND and WD mitochondria, a 
significant upregulation of the proportion of C18:1 was detectable upon WD 
feeding (Tab. 7). To figure out whether alterations in mitochondrial FA composition 
are triggered by differences in chow FA composition or if they are mainly caused 
by FA metabolization via e.g. SCD1, the FA composition of ND and WD chow was 
analyzed (Tab. 6). The WD chow displayed, in comparison to ND chow, a 5-fold 
higher FA concentration and contained high rates of SFAs such as C12:0, C14:0, 
C16:0 and C18:0 (Tab. 6). In contrast, ND chow revealed C18:2 (PUFA) as major 
component and contained almost no SFAs. However, the amount of C18:1 was 
similar in ND and WD chow (Tab. 6). Thus, FA changes in WD mitochondria were 
not caused by the altered FA composition in the diet but due to metabolic 
adaptions, possibly by upregulation of SCD1. 
 
Tab. 6: Fatty acid composition of WD and ND chow 
Fatty acid content is displayed in mg FA per g chow (n=3). *Significant to age-matched control. 
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Sniff 
(ND) 
[mg/g] 
n.d. n.d. 
0.17 6.02 0.22 0.12 0.10 1.18 
n.d. 
7.09 0.55 16.97 1.94 0.12 0.20 
n.d. 
34.62 
± ± ± ± ± ± ± ± ± ± ± ± ± 
0.14 1.88 0.10 0.11 0.04 0.45 1.17 0.22 0.57 0.09 0.03 0.03 4.13 
                  Altromin 
(WD)   
[mg/g] 
1.44 68.66 31.66 18.08 0.04 0.04 0.13 13.89 0.16 8.49 0.24 6.22 0.60 0.28 0.09 0.20 150.10 
± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± 
0.54 4.67 0.90 
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0.01 0.00 0.13 0.80  
*** 
0.02 1.66 0.03 1.09 
*** 
0.01   
** 
0.06     
* 
0.02      
* 
0.00 3.72  
*** 
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Tab. 7: Fatty acid composition of mitochondria after 6, 12 and 24 weeks feeding 
FA content is displayed in µg fatty acid methyl ester (FAME) per mg mitochondrial protein (n=4). 
The distribution of FA classes is presented in percent. n.d. not detected, *Significant changes to 
age-matched controls (bold). 
 
6 weeks 12 weeks 24 weeks 
 
ND 
[µg/mg] 
WD 
[µg/mg] 
    ND 
[µg/mg] 
WD 
[µg/mg] 
    ND 
[µg/mg] 
WD 
[µg/mg] 
C16:0 23.3 ± 2.5 24.4 ± 1.5 30.3  ± 9.9 28.0  ± 2.8 21.1 ± 3.0 22.24 ± 1.1 
C16:1n7c 2.6 ± 1.3 2.5 ± 1.0 2.5  ± 0.7 3.5  ± 2.0 1.5 ± 0.2 3.0 ±0.2*** 
C18:0 21.5 ± 2.4 23.9 ± 3.9 27.0  ± 9.4 23.9  ± 1.9 20.2 ± 6.7 19.7 ± 1.4 
C18:1n9c 8.5 ± 2.9 8.3 ± 2.1 10.1  ± 3.1 15.5  ± 3.1* 6.4 ± 1.0 11.7  ± 1.8** 
C18:1n7c 3.3 ± 1.4 3.4 ± 1.1 3.6  ± 1.1 6.3  ± 1.0* 2.5 ± 0.4 5.6  ±0.6*** 
C18:2n6c 16.0 ± 2.3 18.5 ± 2.8 23.7  ± 7.7 14.3  ± 1.2 15.7 ± 3.1 11.0 ± 0.6 
C20:2n6c n.d.    n.d.       n.d. 2.0  ± 0.6        n.d. 0.97 ± 0.2 
C20:3n6c 1.2 ± 0.9 1.4 ± 0.4 2.3  ± 0.8 2.8  ± 0.6 2.9 ± 0.8 3.7 ± 0.5 
C20:4n6c 13.8 ± 1.8 15.6 ± 1.8 20.1  ± 7.3 18.4  ± 2.6 14.1 ± 2.6 14.7 ± 1.4 
C24:0 n.d.   n.d.       n.d. 0.9  ± 0.1        n.d. 0.95 ± 0.3 
C22:6n3c 4.2 ± 0.6 5.0 ± 0.7 6.6 ± 2.6 5.3  ± 0.8 5.5 ± 1.0 4.7 ± 0.7 
total 94.5 ± 12.0 103 ± 10.7 126  ± 41.6 121  ± 13.3 90.5 ± 8.4 99.8 ± 5.4 
SFA [%] 47.5  ± 2.4 46.9  ± 0.6 45.4  ± 2.2 43.5  ± 3.6 45.8  ± 8.5 43.6  ± 1.2 
MUFA [%] 15.0  ± 4.3 13.7  ± 3.1 13.0  ± 1.4 20.9  ± 3.0** 11.6  ± 1.9 21.0 ±1.1*** 
PUFA [%] 37.4  ± 4.1 39.5  ± 3.6 41.5  ± 3.0 35.6  ± 1.6* 42.6  ± 7.1 35.4  ± 0.2 
Ratio:             
unsat./sat. 1.11  ± 0.1 1.13  ± 0.0 1.21  ± 0.1 1.29  ± 0.2 1.23  ± 0.4 1.29  ± 0.1 
16:1/16:0 0.11  ± 0.1 0.10  ± 0.0 0.08  ± 0.0 0.12  ± 0.1 0.07  ± 0.0 0.14 ±0.0*** 
18:1/18:0 0.40  ± 0.1 0.35  ± 0.1 0.38  ± 0.0 0.65  ± 0.2* 0.34  ± 0.1 0.59  ± 0.1* 
18:1/18:2 0.77  ± 0.4 0.65  ± 0.3 0.59  ± 0.1 1.51 ± 0.2*** 0.58  ± 0.1 1.57  ± 0.3** 
 
In order to investigate whether WD-induced changes in the mitochondrial FA 
composition influence the mitochondrial membrane properties, fluorescence 
anisotropy measurements were performed using DPH or TMA-DPH staining. The 
fluorescence dye DPH incorporates into the inner-lipid phase, while TMA-DPH 
attaches to the lipid-water interphase (Fig. 11A). Depending on the motility of the 
respective membrane phase, the fluorescence dyes rotate and scatter light more 
strongly, indicating higher membrane fluidity. At 24 weeks WD feeding, differences 
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in DPH but not in TMA-DPH anisotropy were present compared to ND controls 
(Fig. 11B-D). Thus, fluidity changes occurred especially in the inner lipid phase, 
supporting the idea that mitochondria adapt upon lipid supply with incorporation of 
FAs into mitochondrial membranes and possibly cause structural modifications of 
mitochondria in NAFLD. Whether these WD-induced molecular alterations 
influence mitochondrial function as well is addressed below. 
 
 
 
 
 
 
 
 
 
 
Fig. 11: Fluorescence anisotropy measurements of mitochondria after 24 weeks feeding  
(A) Schematic overview of DPH and TMA-DPH incorporation into phospholipid bilayers (adapted 
from: Grebowski et al. 2013 [115]). (B) Quantification of anisotropy values demonstrates changes 
in DPH but not in TMA-DPH fluorescence as well as equal values after detergent (Triton) addition 
in WD compared to ND membranes (biological replicates N=2, technical replicates n=6). 
(C, D) Average anisotropy curves are shown for DPH and TMA-DPH measures. *Significant 
changes to age-matched control (bold).  
 
3.1.5 Western diet is associated with energetic deficits but not with elevated 
ROS production  
As the WD nutrition caused mitochondrial membrane modifications (3.1.4), the 
functional integrity of the inner mitochondrial membrane (IM) was studied by 
measuring the time-dependent stability of the mitochondrial membrane potential 
 
DPH TMA-DPH 
 Buffer Triton Buffer Triton 
ND 
188.8 ± 
4.0 
145.7 ± 
0.6 
252.5 ± 
7.9 
309.0 ± 
2.1 
WD 179.5 ± 
4.1 
146.1 ± 
1.3 
252.8 ± 
3.2 
309.0 ± 
3.3 
 
** n.s. n.s. n.s. 
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(MMP), following Rh123 fluorescence. The positively charged fluorescence dye 
Rh123 is quenched during accumulation in mitochondria (inside negatively 
charged) with an intact IM, resulting in low RFU (relative fluorescence units). After 
dissipating the MMP with the protonophore FCCP, the dye is released, leading to 
an increase of RFU (Fig. 12A). Calculating the ratio before and after FCCP 
addition (+/- FCCP) allows a statement according to the mitochondrial MMP 
stability. Neither 6, 12 nor 24 weeks of WD feeding affected the MMP stability 
(Fig. 12B). The stable membrane potential was in line with an unaffected 
mitochondrial H2O2 production at 6 and 24 weeks of WD feeding (Fig. 12C). In 
contrast, mitochondrial ATP production capacity was significantly reduced in WD 
mitochondria, isolated from 12 weeks fed mice (Fig. 12D).  
 
 
 
 
 
 
 
 
 
 
Fig. 12: Mitochondrial functional analyses upon western diet feeding 
(A) Isolated mitochondria present a time-stable membrane potential (MMP) as representatively 
shown for the 12 weeks feed. (B) Quantitative evaluation of MMP stability determined by the ratio 
+/- FCCP addition reveals no changes upon WD feeding (6 wk: n=8, 12 wk: n=7, 24 wk: n=5). 
(C) H2O2 production does not differ between ND and WD liver mitochondria at 6 (n=7) and 
24 weeks feeding (n=4). Substrates are succinate/rotenone (Suc./Rot.), glutamate/malate 
(Glu./Ma.) or palmitoylcarnitine/malate (Palc./Ma.) either in the presence or in absence of ADP. 
(D) Mitochondrial ATP production decreases upon WD compared to ND control (6 wk: n=8, 12 wk: 
n=4). *Significant to age-matched control.  
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Since membrane lipid alterations affect the structural organization of the oxidative 
phosphorylation complexes into mitochondrial supercomplexes (SC) [116] and 
might therefore cause the observed energetic deficits, the mitochondrial  
SC-formation was determined by blue native gel electrophoresis (Fig. 13). 
Modified SC assembly appeared in WD compared to ND mitochondria but 
displayed inhomogeneous changes (Fig. 13B). In detail, WD compared to ND 
mitochondria demonstrated decreased SC-CI expression from 6 to 24 weeks 
feeding. SC-CIII and SC-CIV expression was reduced after 6 weeks and was 
elevated after 24 weeks of feeding (Fig. 13B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 13: Western diet influences mitochondrial supercomplex assembly 
(A) Representative immunoblots of supercomplexes (SC) containing complex I, III and IV are 
pictured together with complex II expression after blue native gel electrophoresis. (B) Quantification 
of SC-CI, SC-CIII and SC-CIV levels relative to complex II demonstrate distinct regulation upon WD 
compared to ND control (6+12 wk: n=5; 24 wk: n=4). *Significant to age-matched control. 
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3.2 Western diet-related mitochondrial adaptions occur 
upstream of NLRP3 inflammasome activation 
3.2.1 Western diet-related mitochondrial changes after 24 weeks of feeding 
Upon 24 weeks of WD feeding, a similar rise in body weight (Fig. 14A), visceral fat 
mass (Fig. 14B) and liver TG accumulation (Fig. 14C) occurred in NLRP3-/- and  
IL-18R-/- mice compared to C57BL/6 wildtype mice. While NLRP3-/- mice revealed 
a slight increase in the hepatocyte death marker ALT, similar to wildtype mice, this 
effect was not present in IL-18R-/- mice (Fig. 14D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 14: NLRP3 inflammasome-deficient mice likewise present obesity and liver steatosis 
but a different shape of liver damage 
(A-C) Western diet induces rise in body weight (A), visceral fat mass (B) and liver TG content (C, 
ND: n=4, WD: n=3) in NLRP3
-/-
 and IL-18R
-/-
 mice equally to wildtype (WT) mice. (D) Serum ALT 
levels are elevated in WT and NLRP3
-/-
 but not in IL-18R
-/-
 mice upon 24 weeks of WD feeding 
(WT: n=8; NLRP3
-/-
 ND: n=2, WD: n=4; IL-18R
-/-
: n=4).  
 
Despite the differently displayed hepatocyte toxicity, identical mitochondrial 
structure modifications appeared in NLRP3-/- as well as in IL-18R-/- mice compared 
to wildtypes (Fig. 15). WD feeding induced widened and rounded cristae 
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(Fig. 15A). As in wildtype mice, these mitochondrial structural alterations 
correlated in NLRP3-/- mice with significantly increased membrane fluidity in the 
inner lipid phase (DPH) but not in the lipid-water interphase (TMA-DPH, Fig. 15B) 
of isolated mitochondria. Moreover, the mitochondrial energy production was 
declined in WD-fed IL-18-R-/- mice compared to ND-fed controls (Fig. 15C).  
 
 
 
 
 
 
 
 
 
 
Fig. 15: NLRP3 inflammasome-deficient mice displays similar mitochondrial modifications 
as wildtype mice 
(A, B) Representative electron micrographs demonstrate ballooned and widened cristae (arrow) in 
NLRP3
-/-
 (A) and IL-18R
-/-
 mice (B, scale bar: 1 µm). (C) DPH- and TMA-DPH fluorescence 
anisotropy of NLRP3
-/- 
ND and WD mitochondria (ND: N=2, n=4; WD: N=4, n=8; N biological 
replicates, n technical replicates). (D) ATP production capacity of IL-18R
-/-
 mitochondria is 
presented relative to ND control (n=3). *Significant changes to ND control (bold). 
 
3.2.2 Western diet-related mitochondrial changes after 48 weeks of feeding 
Upon 48 weeks of WD feeding, wildtype, NLRP3-/- and IL-1R-/- mice demonstrated 
elevated body (Fig. 16A) as well as liver weight (Fig. 16B) and increased visceral 
fat mass (Fig. 16C) compared to ND-fed mice. The liver damage marker ALT was 
strongly elevated in serum of WD-fed wildtype, NLRP3-/- and IL-1R-/- mice, 
therefore indicating steatosis progression to NASH. 
 
DPH TMA-DPH 
 Buffer Triton Buffer Triton 
ND 
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1.3 
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7.3 
299.5 ± 
1.89 
WD 
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133 ± 
3.4 
240 ± 
13.6 
305 ± 
3.2 
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Fig. 16: Forty-eight weeks of western diet induces hepatocyte damage  
(A-C) Western diet raises the body weight (A), liver weight (B) and mass of visceral fat (C) in  
NLRP3
-/-
 and IL-1R
-/-
 mice equally compared to wildtype (WT) mice. (D) Serum ALT levels are 
elevated upon 48 weeks of WD feeding. (NLRP3
-/-
 ND: n=3, WD: n=7; WT WD: n=4; IL-1R
-/-
: n=2; 
ALT IL-1R
-/-
 ND: n=9, WD: n=7).  
 
At mitochondrial level, WD NLRP3-/- and IL-1R-/- mitochondria demonstrated higher 
membrane fluidity (lower DPH anisotropy, Fig. 17A, B) and less stable MMP 
(Fig. 17C). Forty-eight weeks of WD slightly raised the mitochondrial H2O2 
production in wildtype, NLRP3-/- and IL-1R-/- mice, especially with palmitoyl-
carnitine as substrate (Fig. 17D).  
Thus, steatosis-related mitochondrial adaptions, which are equally present in 
NLRP3 inflammasome-deficient and wildtype mice, are upstream of NLRP3 
inflammasome activation. Furthermore, as they appeared likewise in immune-
compromised mice with slightly or no liver damage (Fig. 14D), they are insufficient 
to cause pronounced hepatocyte death. On the contrary, since mitochondrial 
dysfunction such as reduced MMP stability and elevated ROS production were 
present together with elevated ALT level after 48 weeks of feeding, these 
alterations seem to be late occurring mitochondrial impairments that are 
associated with liver damage. 
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Fig. 17: Mitochondrial modifications after 48 weeks of western diet feeding 
(A, B) DPH fluorescence anisotropy is lowered in NLRP3-/- (A, n=3) and IL-1R-/- (B, n=2) WD 
compared to ND mitochondria (arrow, triton addition). (C) The ratios +/- FCCP addition display less 
stable MMP in NLRP3
-/-
 mitochondria upon WD feeding (NLRP3
-/-
 ND: n=4, WD: n=7; 
WT WD: n=4; IL-1R
-/-
: n=2). (D) Mitochondrial H2O2 production is elevated in WD mitochondria with 
succinate+ADP (Suc/R+ADP) or palmitoylcarnitine/malate (PA/MA) but not with succinate/rotenone 
(Suc/R) as substrate (NLRP3
-/-
 ND: n=3, WD: n=6; WT WD: n=3; IL-1R
-/-
: n=2). 
 
3.3 Western diet mitochondria display an increased sensitivity to 
calcium  
An altered mitochondrial membrane lipid composition influences calcium flux 
across mitochondrial membranes [117, 118] and elevated calcium levels have 
been reported in NASH-related inflammation [119, 120]. Therefore, it was 
analyzed whether WD influences mitochondrial calcium susceptibility. Isolated 
mitochondria from C57BL/6 mice were treated with 50 µM calcium and membrane 
potential (MMP)-loss as well as mitochondrial membrane permeability transition 
(MPT) were measured (Fig. 18). WD mitochondria revealed an earlier disruption of 
MMP and MPT upon calcium treatment most prominently after 12 weeks of 
feeding (Fig. 18). The time of start, end, duration and the time point of maximal 
depolarization (max slope) were calculated (Tab. 8) to compare and quantify 
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mitochondrial MMP-loss between ND and WD nutrition. In particular, after 6 and 
12 weeks feeding, WD mitochondria displayed significant earlier start, end or max 
depolarization (Tab. 8). Thus, WD nutrition increased the sensitivity of 
mitochondria to elevated calcium levels.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 18: Earlier destruction of mitochondrial MMP and MPT upon calcium treatment 
(A, B) Isolated WD mitochondria treated with 50 µM Ca²
+
 present earlier MMP-loss (A, 6 wk: n=8, 
12 wk: n=3, 24 wk: n=5) and MPT (B, 6 wk: n=4, 12 wk: n=3, 24 wk: n=5) than ND mitochondria.  
 
Tab. 8: Characterization of mitochondrial depolarization  
Time calculation [min] of start, end, max and duration of depolarization upon 50 µM calcium 
treatment (n: number of animals, square bracket: technical replicates). *Significant to age-matched 
control (bold). 
Depolarization period [min]   
 
Start Max End Duration 
6 wk       
(n=8), [10] 
ND 11.3 ± 14.3 31.3 ± 13.2 40.1 ± 14.5 28.8 ± 5.7 
WD 3.1 ± 4.2 17.9 ± 4.2* 27.5 ± 5.5* 24.4 ± 4.5 
12 wk        
(n=6), [8] 
ND 12.8 ± 14.0 30.5 ± 12.0 45.8 ± 15.6 33.0 ± 5.8 
WD 6.3 ± 7.3 20.0 ± 4.6* 32.3 ± 7.5 26.0 ± 3.2* 
24 wk            
(n=5), [5] 
ND 5.5 ± 6.6 15.5 ± 8.3 26.7 ± 12.3 21.2 ± 8.7 
WD 2.3 ± 3.6 11.2 ± 6.0 19.7 ± 9.0 19.2 ± 7.8 
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3.4 Western diet aggravates mitochondrial impairments in an 
animal model for Wilson disease 
As WD nutrition caused mitochondrial impairments (3.1) and elevated the 
sensitivity to calcium (3.3), it was studied whether mitochondrial dysfunctions 
promote the development of liver damage. WD feeding may target mitochondria as 
copper overload in Wilson disease does. Therefore, the effect of WD nutrition on 
Wilson disease progression was determined. Wilson disease is a copper storage 
disease, caused by mutations in the copper transporter ATP7B. Atp7b-/- LPP rats 
were used as animal model for Wilson disease since they develop hepatic copper 
accumulation, liver inflammation and mitochondrial impairments similar to Wilson 
patients [69-71]. Heterozygous Atp7+/- LPP rats do not develop a Wilson 
phenotype and function as controls.  
Similar to C57BL/6 mice, WD-fed LPP rats demonstrated enhanced triglyceride 
(Fig. 19A) and visceral fat (Fig. 19B) accumulations. Moreover, WD induced liver 
damage (raised AST, Fig. 19C) and mitochondrial copper accumulation in Atp7b-/- 
rats (Fig. 19D). Interestingly, mitochondrial copper was slightly elevated in WD-fed 
Atp7b+/- rats as well (Fig. 19D). 
 
 
 
 
 
 
 
 
Fig. 19: Western diet induces steatosis, liver damage and mitochondrial copper 
accumulation in LPP rats 
(A, B) WD causes liver triglyceride (A, n=5) and visceral fat mass accumulation (B, n=6) in Atp7b
+/-
 
and Atp7b
-/-
 rats. (C) AST is elusively enhanced in WD fed Atp7b
-/-
 rats (ND: n=8; WD: n=6). 
(D) Mitochondrial copper load increases due to WD feeding (n=6).  
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The mitochondrial membrane fluidity, measured by DPH fluorescence, was not or 
slightly reduced in Atp7b+/- or Atp7b-/- rats, respectively (Fig. 20A, B). WD feeding 
impaired the ability to inhibit calcium-induced MPT by cyclosporine A. Thus, 
calcium supplementation caused earlier MPT induction in WD mitochondria from 
Atp7b+/- rats compared to ND mitochondria and this was further shortened in WD 
Atp7b-/- mitochondria (Fig. 20C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 20: Western diet promotes mitochondrial deficits in Atp7b
-/-
 rats 
(A, B) The average DPH fluorescence does not differ between ND and WD mitochondria in Atp7b
+/-
 
rats (A, n=5) but displays a slight reduction in Atp7b
-/-
 rats (B, n=5). (C) WD impairs calcium-
induced MPT inhibition by cyclosporine A (CysA: 5 µM, Ca
2+
: 100 µM, n=5). (D) WD decreases 
ATP production capacity in Atp7b
+/-
 rats and more pronounced in Atp7b
-/-
 rats (n=5). (E) The 
F1FO-activity normalized to citrate synthase (CS) declines in Atp7b
-/-
 mitochondria upon WD 
feeding (n=5). (F) Mitochondrial H2O2 production (substrates: succinate, ADP) increases in WD 
Atp7b
-/-
 rats (n=5). 
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Comparable to WD-fed mice, a significant decrease in ATP production capacity 
occurred in WD mitochondria from Atp7b+/- rats and this was further reduced in 
mitochondria from WD-fed Atp7b-/- rats (Fig. 20D). This reduction in energy 
production of Atp7b-/- rats was associated with lower ATP-synthase (F1FO) activity 
(Fig. 20E) normalized to the activity of the mitochondrial housekeeping enzyme 
citrate synthase (CS). As observed in mice, WD was insufficient to cause 
mitochondrial ROS production in Atp7b+/- rats, but appeared in Atp7b-/- rats 
(Fig. 20F) that are associated with mitochondrial copper accumulation and liver 
damage (Fig. 19C, D). Thus, WD aggravated mitochondrial copper accumulation, 
amplified mitochondrial deficits and promoted liver damage in Wilson disease.  
 
3.5 The Western diet-related steatosis cell culture model 
highlights C18:1 as protective contributor in NAFLD 
To unravel the underlying mechanisms that trigger WD-related mitochondrial 
dysfunction and to understand why such nutrition is stable without developing liver 
damage, a steatosis cell culture model was established based on the fatty acid 
composition of mouse livers from 24 weeks fed mice (Fig. 21). Standard liver fatty 
acid composition (SLFC) and high fat liver composition (HFLC) were compared 
regarding to their fattening potential, hepatocyte toxicity and influence on 
mitochondrial functionality.  
 
 
 
 
Fig. 21: Standard liver fatty acid composition (SLFC) and high fat liver composition (HFLC) 
determined from mouse livers after 24 weeks of feeding. 
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3.5.1 Elevated C18:1 levels in cell culture media cause intracellular lipid 
accumulation  
HepG2 cells were treated with SLFC or HFLC for 48 h and fat accumulation was 
determined by Nile Red staining. Both fatty acid mixtures induced progressive fat 
accumulation in HepG2 cells compared to vehicle control albumin, displayed as 
increased fluorescence signal as well as enhanced granularity in transmitted light 
micrographs (Fig. 22). The quantification of the fluorescence signal revealed a 
higher quota of fat accumulation in HFLC compared to SLFC particularly at doses 
of 125 µM or 250 µM, respectively (Fig. 23A). 
 
 
Fig. 22: Fat accumulation in HepG2 cells through SLFC and HFLC supplementation 
Representative transmitted light micrographs (upper lane) demonstrate an enhanced granularity in 
HepG2 cells treated for 48 h with 125 µM SLFC or HFLC compared to albumin. Nile Red 
fluorescence is shown for 125 µM (middle lane) and 550 µM (lower lane) FA treatment. 
Scale bar: 200 µm. 
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To determine which FA of the SLFC or HFLC mixture promotes this difference in 
fat accumulation, HepG2 cells were treated with each fatty acid alone and the 
fattening potential of HFLC compared to SLFC was calculated. In detail, the 
difference of the relative amount between HFLC vs. SLFC of each FA was 
calculated first. Then, the measured fat increase (Fig. 23B) was multiplied, 
resulting in the fattening potential of the indicated FAs (Fig. 23C). This calculation 
presented C18:1 as the major determinant (94%) for fat accumulation in HFLC. 
The overall fattening potential of HFLC was calculated to be ~15% higher than the 
fattening potential of SFLC (Fig. 23C). This theoretical value was in conformity to 
the mean fat increase, analyzed by Nile Red stain (125 µM: 16%, 250 µM: 19% 
higher in HFLC compared to SLFC, Fig. 23A). Thus, the elevated fattening 
potential of HFLC, which reflects the FA composition of WD liver, is mainly caused 
by high concentrations of C18:1.  
 
 
 
 
 
 
Fig. 23: Quantitative analysis of fat accumulation 
and calculation of the fattening potential 
(A) Quantification of Nile Red fluorescence of HepG2 
cells, treating for 48 h with SLFC (125 µM: n=6, 
250 µM: n=3, 550 µM: n=7), HFLC (125 µM: n=5, 
250 µM: n=5, 550 µM: n=11) or albumin (125 µM: 
n=2, 250 µM: n=5, 550 µM: n=8). (B) Cell fat content 
upon 24 h incubation with 250 µM of the indicated 
fatty acids normalized to albumin (n=5). 
(C) Calculation of the fattening potential of HFLC 
compared to SLFC medium. 
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3.5.2 Elevated C18:1 levels in cell culture media avoids toxicity of saturated 
fatty acids 
Each FA of the SLFC and HFLC mix was individually applied for 24 h (250 µM) to 
HepG2 cells, measuring their toxic potential. The FAs C16:0 and C20:4 decreased 
the cell viability compared to albumin, whereas C18:0, C18:1 and C18:2 displayed 
no cell-toxic effects (Fig. 24A).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 24: HFLC maintains HepG2 cell viability because of high rates of C18:1 
(A) HepG2 cell viability decreases upon C16:0 and C20:4 supplementation but not upon C18:0, 
C18.1 or C18:2 addition (250 µM, 24 h, n=3). (B) Forty-eight hour treatment of HepG2 cells with 
albumin (Alb, 250 µM: n=5, 550 µM: n=11), SLFC (250 µM: n=2, 550 µM: n=5) or HFLC (250 µM: 
n=3, 550 µM: n=5) presents no hepatocyte toxicity. (C-E) Inhibition of SCD1 (CAY-10566, 15 µM, 
48 h) induces HepG2 cell death in C16:0 and C18:0 but not in C18:1 cultivated cells (C, 550 µM, 
n=3). C18:1 addition to C16:0 and C18:0 treated cells restores HepG2 cell viability (D, 550 µM, 
48 h, n=3). SCD1 inhibition decreases HepG2 cell viability in SLFC but not in albumin or HFLC 
cultivated cells (E, 550 µM, 48 h, n=4; # significant to 275 µM SLFC p<0.001). *Significant to  
non-inhibited control. 
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HFLC and SLFC consist of approximately 41% C16:0 and C20:4 (Fig. 21) but 
these FA mixtures did not induce any hepatocyte death if they were applied for 
48 h to HepG2 cells (Fig. 24B). Therefore, the other non-toxic FAs in HFLC and 
SLFC possibly counteract this lipotoxicity. Prior reports have demonstrated that 
C18:1 rescues C16:0-induced hepatocyte death [25, 28-30]. Therefore, different 
proportions of C18:1 and SFAs, e.g. C16:0 and C18:0, were tested for cellular 
toxicity. Additionally, the SFA-transforming enzyme, SCD1, was blocked with 
CAY10566 [121] to analyze whether an active SCD1 desaturase protect against 
SFA toxicity.  
SCD1 inhibition strongly decreased the viability of cells treated with SFAs (C16:0, 
C18:0) but did not cause any cell death if C18:1 was applied to the medium 
(Fig. 24C). In the presence and absence of CAY10566, the addition of C18:1 to 
C16:0 (1:3) restored HepG2 cell viability completely, while higher rates of C18:1 
(50%) were necessary to rescue C18:0-induced toxicity in the presence of the 
SCD1 inhibitor (Fig. 24D). Thus, if C18:0 is not metabolized to C18:1 or if only low 
amounts of C18:1 are present, this causes elevated hepatocyte death. 
Consequently, SLFC compared to HFLC is highly cell toxic upon SCD1 inhibition 
(Fig. 24E). Therefore, the upregulation of SCD1 and synthesis of C18:1 during WD 
nutrition function as protective mechanisms against excessive nutritional supply of 
SFAs in vivo. 
It has been reported that SFAs (especially C16:0) display an increased hepatocyte 
toxicity if the cellular recycling (autophagy) of lipid droplets or dysfunctional 
mitochondria is blocked via 3-methyladenine (3-MA) [122]. 3-MA inhibits 
phosphatidylinositol 3-kinases and blocks autophagosome formation [123]. 
Therefore, the next analysis addressed the issue whether a high content of C18:1 
in HFLC compared to SLFC is beneficial in case of autophagy inhibition as well. In 
agreement, SLFC but not HFLC or albumin cultivated cells demonstrated 
hepatocyte death in the presence of 3-MA (Fig. 25).  
These findings indicate that lipotoxicity depends on the FA species that are 
provided to hepatocytes (chow fat composition) and if an adaption (C18:1 
synthesis) is possible. In this context, the C18:1-caused elevated fat accumulation 
seems to be accepted by hepatocytes as non-toxic side effect.  
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Fig. 25: Autophagy inhibition impairs HepG2 cell 
viability upon SLFC supplementation 
Blocking autophagy via 3-methyladenine (3-MA, 
89.3 µM, 24 h) leads to HepG2 cell viability loss in 
SLFC treated cells but not in HFLC or albumin treated 
cells (550 µM FA: n=4, +3-MA: n=3; # significant to 
550 µM SLFC p<0.001). 
 
3.5.3 Fatty acid-induced mitochondrial changes in vitro are similar to those 
in steatotic mice 
FA supply during WD nutrition induced lipid membrane changes (3.1.4) and 
mitochondrial dysfunction in mice livers (Fig. 12). Whether these alterations 
likewise occur in vitro was further investigated. Incubating HepG2 cells for 48 h 
with 550 µM HFLC revealed, equally to WD feeding, an enrichment of C18:1 in 
mitochondrial membranes (Fig. 26A) and a declined mitochondrial ATP production 
capacity (Fig. 26B) relative to albumin. 
 
 
 
 
 
 
Fig. 26: FA-induced mitochondrial impairments 
(A, B) Isolated mitochondria from HFLC treated cells 
(550 µM, 48 h) display an altered FA composition (A, 
Alb: n=2, HFLC: n=3) and an decreased ATP 
production (B, n=9) compared to albumin. (C) DiOC6 
staining of HepG2 cells reveals an impaired 
mitochondrial membrane potential in SLFC (n=3) but 
not in albumin (n=5) or HFLC (n=4) treated cells.  
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Moreover, mitochondrial membrane potential (MMP) was not affected in HFLC 
treated cells (Fig. 26C) compared to albumin, which was analyzed by DiOC6 
staining. DiOC6 is a positively charged fluorescence dye that accumulates in 
mitochondria with an intact MMP (inside negatively charged). In contrast, the 
addition of SLFC, which is rich in C18:0 and low in C18:1, induced a significant 
reduction in the amount of cells with an intact MMP (Fig. 26C). Therefore, the 
incorporation of C18:1 into mitochondrial membranes seems to be associated with 
a defective energy production independent of the disruption of the MMP. 
 
3.6 L-carnitine supplementation increases fatty acid oxidation 
and avoids steatosis-related mitochondrial impairments 
During steatosis, FA oxidation has been suggested to be impaired [12]. L-carnitine 
supplementation favors FA-uptake into mitochondria and consequently augments 
ß-oxidation, implicating improved liver function and decreased fat accumulation in 
NAFLD rodents and humans [124-127]. Thus, L-carnitine is discussed as potential 
therapeutic intervention in NAFLD. In the above introduced steatosis cell culture 
model, C18:1 and C18:2 demonstrated the highest fattening potentials of all tested 
FAs (Fig. 23). For these reasons, the influence of an improved fatty acid oxidation 
on mitochondrial function was addressed, treating HepG2 cells with C18:1 and 
C18:2 in the presence or absence of L-carnitine. First, the fattening capacities of 
C18:1 and C18:2 were reconfirmed and demonstrated a dose dependent lipid 
accumulation in HepG2 cells, which was more pronounced for C18:2 
supplementation at the highest dose (Fig. 27A). To exclude a lower lipid 
accumulation because of potential cell death, the fluorescence intensity of Nile 
Red staining was normalized to cell density (determined by Hoechst staining) and 
additionally Neutral red viability assay was performed. Twenty-for hour treatment 
with C18:1 or C18:2 did not induce any cell-toxic effects neither with a 
concentration of 275 µM nor 1.1 mM (Fig. 27B). For further investigations, the 
concentration of 275 µM FA was chosen to study the effect of L-carnitine on lipid 
accumulation and mitochondrial functionality.  
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Fig. 27: L-carnitine restores mitochondrial function after fatty acid supplementation  
HepG2 cells are treated for 24 h with 275 µM C18:1, C18:2 or additional 275 µM L-carnitine. 
(A) Both FAs cause a dose-dependent increase in cellular fat accumulation, which is more 
pronounced for C18:2 supplementation (n=5, # significant to albumin). (B) Cell viability is not 
affected up to 1.1 mM FA treatment (n=3). (C) L-carnitine addition reduces fat accumulation in 
HepG2 cells (n=3). (D-F) High resolution respirometry reveals elevated carnitine-induced oxygen 
flux (D, n=5) and lower C18:2-induced ratios of routine/leak and ETS/leak respiration (E, F 
Alb: n=10, FAs: n=8, Carn: n=6). (G) C18:2 treatment rises the amount of HepG2 cells with high 
mitochondrial ROS production that is lowered by L-carnitine addition (Alb, FAs: n=9, Carn: n=4). 
(H) Cellular ATP content is decreased by C18:1 and C18:2 application and is rescued through 
carnitine addition (Alb/FAs: n=7, Carn: n=5).  
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The addition of L-carnitine reduced cellular lipid accumulation, especially of C18:2 
(Fig. 27C), indicating improved fatty acid oxidation. In agreement, the 
mitochondrial oxygen consumption rates revealed carnitine-dependent elevated 
basal routine and maximal respiration (ETS, Fig. 27D). Calculating the ratios of 
routine/leak or ETS/leak respiration demonstrated slightly lower ratios upon C18:2 
treatments compared to albumin or C18:1, which were almost not improved by 
L-carnitine addition (Fig. 27E, F). Therefore, C18:2 but not C18:1 seem to cause 
elevated membrane leakage. The mitochondrial ROS production was followed by 
flow cytometry and Mitosox staining. Particularly, C18:2 treatment induced a 
significant rise of cells with high mitochondrial ROS production, which was 
downregulated in cells treated with L-carnitine (Fig. 27G). Moreover, L-carnitine 
supplementation restored FA-induced declines in cellular ATP content (Fig. 27H). 
These results indicate that L-carnitine treatment promotes FA oxidation, which is 
followed by decreased lipid accumulation, reduced ROS production and 
re-established cellular ATP levels.  
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4. Discussion
NAFLD is the most common liver disorder in western society and 
malnutrition-caused obesity is rising worldwide [6]. NAFLD is a slowly deteriorating 
disease and only a minority of NAFLD patients progress to the more severe liver 
disease state NASH. Nevertheless, the underlying molecular mechanisms that 
cause steatosis progression to NASH and cirrhosis remain incompletely 
understood. Consequently, therapeutic strategies are mostly lacking and 
NASH-related cirrhosis is the third most common cause of death worldwide [6]. 
Mitochondrial structure changes and functional impairment of liver mitochondria 
have been frequently described in NAFLD and NASH. However, at what stage of 
the liver disease, which mitochondrial alterations occur, and the underlying 
molecular mechanisms that cause these alterations are still a matter of debate. 
One major reason for this lack of understanding is the diversity of NAFLD animal 
and feeding models that only partially reflect the human situation. Therefore, a 
high fat and fructose-rich diet (western diet, WD), which resembles human 
nutrition in western society, was fed to mice for 6 to 48 weeks and isolated 
mitochondria were analyzed regarding their molecular composition and 
biochemical function.  
4.1 Western diet causes steatosis and induces molecular 
adaptations in mitochondria due to lipidome changes 
In accordance to findings in humans, WD feeding induced obesity and steatosis in 
mice. A progressive elevation of body weight, visceral fat mass and increased 
triglyceride (TG) accumulation were observed upon 6 to 24 weeks of WD feeding 
(Fig. 7). Enhanced serum ALT levels only occurred after nearly life-long western 
diet nutrition (48 weeks in mice, Fig. 16). Thus, steatosis only slowly progresses to 
overt liver damage in WD-fed mice and resembles the human situation in which 
only a minority of NAFLD patients progress to the severe liver disease state 
NASH. Despite this, mitochondrial molecular alterations such as lipidome changes 
and structural impairments appeared already after 6 and 12 weeks of feeding. As 
WD chow contains mainly saturated fatty acids (SFA, 90%, Tab. 6), an 
unexpected rise in mitochondrial monounsaturated fatty acid (MUFA) levels were 
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observed in WD mitochondria while the amount of SFAs was unchanged between 
ND and WD mitochondria. Especially oleic acid (C18:1) was enriched and linoleic 
acid (C18:2) was decreased upon WD feeding in mitochondrial membranes 
(Tab. 7). This WD-induced alteration in mitochondrial FA composition was 
paralleled by increased mitochondrial membrane fluidity (Fig. 11) and altered 
mitochondrial structures (ballooned cristae, Fig. 9). In contrast, the proteome of 
WD mitochondria was highly comparable to age-matched ND mitochondria. Only 
2–6% of all identified proteins were enriched or depleted in WD compared to ND 
mitochondria (Tab. 5). Furthermore, the total protein content per mitochondrion did 
not differ between ND and WD mitochondria, i.e., both mitochondrial populations 
appeared with a protein content of approximately 0.15 pg per mitochondrion. 
Therefore, the present study indicates that mitochondrial structure changes in 
NAFLD, e.g. ballooned and widened cristae, are most probably caused by 
mitochondrial membrane lipid changes. These alterations occur in parallel to 
steatosis and are not a result of liver damage. 
Moreover, it was demonstrated that especially C18:1 induces steatosis in 
hepatocytes (Fig. 23). These elevated C18:1 levels are not caused by dietary FA 
composition but rather due to the upregulation of the FA-metabolizing enzymes 
such as ELOVL2, TECR and SCD1. The enzymes ELOVL2 and TECR elongate 
FAs. The desaturase SCD1 incorporates a double bound at position delta-9 and 
metabolizes C16:0 and C18:0 to their monounsaturated counterparts C16:1 or 
C18:1, respectively. SCD1 is located in the mitochondrial-associated membranes 
(MAMs) of the endoplasmic reticulum (ER) that synthesize membrane 
phospholipids (PLs) [128]. These PLs are transported from the MAMs to the outer 
mitochondrial membranes via non-vesicular intermembrane transport [129]. 
Therefore, the increased SCD1 activity in MAMs of WD-fed mice may cause the 
mitochondrial membrane lipid changes in WD mitochondria. Since similar 
upregulations of SCD1 and MUFAs have been described in livers of rodents [11, 
29, 130] and humans [131-134] with NAFLD and/or NASH, SCD1 was blocked in 
the present study to figure out why MUFAs are synthesized due to WD nutrition.  
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4.2 An active SCD1 desaturase protects against excessive 
supply of saturated fatty acids 
Fatty acid treatment of HepG2 cells demonstrated that C16:0 and especially C18:0 
are cell toxic if SCD1 is inhibited (Fig. 24). This elevated toxicity is caused by an 
accumulation of SFAs in hepatocytes, since it has been reported that C16:0 
induces the induction of apoptosis via elevated mitochondrial membrane 
permeability (MPT), the release of cytochrome c and the activation of pro-
apoptotic caspases [22, 24-28]. In the present study, the lipotoxic effect of SCD1 
inhibition in C16:0 and C18:0 cultivated HepG2 cells was reversible by the addition 
of C18:1 (Fig. 24). These findings are in line with prior reports that have 
demonstrated that an addition of C18:1 rescues C16:0-induced toxicity [25, 28-30]. 
The viability of HepG2 cells was neither decreased upon C18:1 supplementation in 
doses up to 1.1 mM (Fig. 27) nor in combination with SCD1 inhibition (Fig. 24). 
However, the intracellular lipid accumulation caused by C18:1 supplementation 
was twofold compared to the lipid accumulation caused by C16:0 or C18:0 
addition (Fig. 23). In agreement, it has been reported that C18:1 displays no 
hepatocyte toxicity but rather enhances lipid accumulating properties [25-27]. Our 
results therefore confirm the conclusions from Flowers et al. [134] and Attie et al. 
[135] that SCD1 upregulation has compensatory effects against high amounts of 
SFAs and correlates with elevated triglyceride (TG) levels. Comparable results 
were shown from Li et al. who have demonstrated that Scd1-/- mice, fed with MCD, 
display increased apoptosis compared to Scd1+/+ mice and that this effect is 
reduced by C18:1 supplementation [29]. Furthermore, these authors have 
demonstrated an increased C16:0-induced apoptosis in HepG2 cells due to SCD1 
silencing and inhibition [29]. In addition, Listenberger et al. have shown that 
overexpression of SCD1 in fibroblasts protects against C16:0-induced toxicity and 
elevates TG accumulation [136]. Altogether, these results establish an increased 
SCD1 activity as protective adaptation against excessive supply of SFAs.  
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4.3 Mitochondrial ATP and ROS production depend on the 
dietary as well as the mitochondrial lipid composition 
In parallel to FAs changes of the mitochondrial membrane, a reduced 
mitochondrial ATP production was found in WD mitochondria after 12 weeks of 
feeding (Fig. 12). Analyzing the assembly of the oxidative phosphorylation 
complexes (SC-formation) demonstrated a reduction of the complex I-containing 
supercomplex (SC-CI) displayed in WD compared to ND mitochondria (Fig. 13). 
As oxidative phosphorylation complex I is the major rate-limiting step in liver 
mitochondrial oxidative phosphorylation [137], this finding might possibly explain 
the decreased energy production of WD mitochondria. Furthermore, in the present 
study, it was shown that WD mimicking FA composition (HFLC) promoted elevated 
C18:1 concentrations in mitochondria of HepG2 cells and that these mitochondria 
demonstrated a lower ATP production capacity compared to albumin controls 
(Fig. 26). Moreover, C18:1 supplementation decreased the cellular ATP content 
(Fig. 27). Taken together, these results imply that the altered mitochondrial 
membrane FA composition in WD mitochondria lowers mitochondrial 
supercomplex I formation thereby possibly causing a reduced mitochondrial ATP 
production capacity. 
Importantly, mitochondria from WD-fed mice up to 24 weeks of feeding (Fig. 12) 
and WD-fed LPP rats (Fig. 20) did not provoke elevated ROS production. 
However, controversial results exist concerning ROS production in animal models 
of steatosis. On the one hand, it has been reported that HFD decreased ROS 
production in liver mitochondria [138, 139]. On the other hand it was shown that 
HFD- and MCD-fed rodents displayed elevated mitochondrial ROS production  
[61-63, 140, 141]. Resolving these contradictories, the dietary lipid composition 
should be considered, since it has been suggested that the mitochondrial ROS 
production could be altered by changes in membrane lipid composition [139, 142, 
143]. In the present study, WD nutrition caused elevated C18:1 and decreased 
C18:2 levels in mitochondrial membranes (Tab. 7) and the supplementation of 
C18:1 to HepG2 cells did not increase mitochondrial ROS production in contrast to 
C18:2 addition (Fig. 27). In agreement, Monteiro et al. have reported that a 
rapeseed oil diet, which is rich in MUFA such as C18:1, decreased hepatic 
mitochondrial H2O2 production [138]. Further, it was demonstrated that C18:2- but 
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not C18:1-rich nutrition induced elevated mitochondrial ROS production in 
lymphocytes causing lymphocyte death in NASH [32-34]. It therefore appears that 
the WD applied in this study causes mainly C18:1 increases and no ROS 
elevation. Consequently, the present thesis showed that the dietary as well as the 
mitochondrial lipid compositions are crucial determinants which mitochondrial 
dysfunctions occur in nutritional-induced steatosis.  
4.4 Improving fatty acid oxidation avoids steatosis-related 
mitochondrial impairments 
Liver steatosis is a reversible process and L-carnitine supplementation has been 
described to decrease fat accumulation in steatotic rodents and humans [124-
127]. However, whether a reduction of steatosis by L-carnitine supplementation 
improves mitochondrial functionality is unknown. Treating HepG2 cells with C18:1 
or C18:2 in the presence of equal doses of L-carnitine demonstrated a decreased 
intracellular lipid accumulation and elevated mitochondrial respiration compared to 
FA-treated cells without L-carnitine supply (Fig. 27). These results imply that 
L-carnitine supplementation, which favors FA uptake into mitochondria, improves 
FA-oxidation and therefore causes decreased fat accumulation. This reduced 
steatosis was paralleled by a decreased mitochondrial ROS production and 
restored cellular ATP levels (Fig. 27). Thus, these findings indicate that a removal 
of these FAs by increased ß-oxidation also avoids mitochondrial membrane 
alterations indicating their potential reversibility. The present study therefore 
highlights the flexibility of mitochondria due to dietary interventions. Thus, theses 
mitochondrial alterations may be rather considered as adaptations and not as 
dysfunctions. In accordance with this conclusion, Koliaki et al. have demonstrated 
that liver mitochondria adapt their respiration in patients with steatosis and that this 
flexibility was lost in patients with NASH leading to elevated oxidative stress [13]. 
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4.5 Steatosis-related mitochondrial adaptations are independent 
of an activated NLRP3 inflammasome 
Low-grade chronic inflammation promotes enhanced liver damage and is a 
hallmark of obesity and NASH. Especially, the NLRP3 inflammasome is active in 
these metabolic disorders [74, 75, 144, 145]. In agreement, feeding C57BL/6 mice 
for 24 weeks with WD increased the mRNA levels of the inflammation markers 
NLRP3 and MCP1 (monocyte chemoattractant protein 1) in WD livers (data not 
shown). It has been reported that the accumulation of dysfunctional and damaged 
mitochondria with, e.g. elevated membrane potential (MMP)-loss, increased 
membrane permeability transition (MPT) and enhanced mitochondrial ROS 
production induced NLRP3 inflammasome activation and liver damage [146, 147]. 
However, whether WD-caused mitochondrial adaptations are up- or downstream 
of an activated NLRP3 inflammasome is still a matter of debate. In this study, 
mitochondria from NLRP3-/-, IL-18R-/- and IL-1R-/- mice appeared with identical 
mitochondrial alterations, e.g. ballooned cristae, elevated membrane fluidity and 
declined ATP production, highly similar to mitochondria from C57BL/6 wildtype 
mice (Fig. 15, Fig. 17). Of note, these mitochondrial changes were also present in 
IL-18R-/- mice who did not develop any liver damage after 24 weeks of feeding 
(Fig. 14, Fig. 15). Thus, the WD-related mitochondrial adaptations are upstream 
and independent of NLRP3 inflammasome activation. Furthermore, these 
adaptations are insufficient to cause pronounced liver damage.  
4.6 Western diet-caused steatosis is a balanced but vulnerable 
situation 
Western diet-induced steatosis caused enhanced liver damage paralleled by 
increased mitochondrial ROS production after nearly life-long WD nutrition 
(48 weeks, Fig. 17). Moreover, the metabolization from SFAs to MUFAs prevented 
hepatocyte death (Fig. 24). Thus, steatosis and mitochondrial alterations remain 
stable quite long without inducing liver damage. However, WD feeding increased 
the sensitivity of mitochondria to cellular stress. Incubating isolated mitochondria 
with calcium demonstrated an earlier MMP-loss and induction of MPT in WD 
compared to ND mitochondria (Fig. 18). This increased sensitivity to calcium was 
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present already after 6 weeks of WD feeding and appeared in 
NLRP3 inflammasome-deficient mice as well (data not shown). It has been 
reported that an elevated membrane fluidity and MUFA-rich nutrition influences 
calcium-induced MPT induction [117, 138]. Therefore, the altered membrane lipid 
composition in WD mitochondria possibly causes the increased calcium sensitivity 
of WD mitochondria. Taken together, these findings imply that conditions that 
cause increased intra- and extracellular calcium levels, e.g. bacterial or viral 
infections and inflammation, would affect WD mitochondria more pronounced than 
ND mitochondria.  
 
4.7 Western diet amplifies mitochondrial deficits and promotes 
Wilson disease progression  
Since steatosis as well as Wilson disease target mitochondria, it was analyzed if 
steatosis-related and copper-related mitochondrial dysfunctions are additive and 
whether this promotes Wilson disease progression. Wilson disease is a copper 
storage disease, caused by mutations in the copper transporter ATP7B [68]. LPP 
rats contain the same genetic defect in Atp7b as Wilson patients. While Atp7+/- 
LPP rats do not develop a Wilson phenotype and function as controls, the Atp7b-/- 
LPP rats display, similar to humans, a Wilson phenotype with hepatic copper 
accumulation, liver damage and mitochondrial impairments [69-71]. In the present 
study, WD-fed Atp7b+/- LPP rats displayed a decreased ATP production capacity in 
comparison to ND-fed rats and an elevated susceptibility to calcium (Fig. 20) 
similar to WD-fed C57BL/6 mice (Fig. 12, Fig. 18). These mitochondrial 
impairments were further aggravated in WD-fed Atp7b-/- LPP rats that 
demonstrated pronounced liver damage but were not present in ND-fed Atp7b-/- 
rats (Fig. 19, Fig. 20). Therefore, WD amplifies mitochondrial sensitivity to calcium, 
augments energetic deficits and promotes Wilson disease progression. Moreover, 
WD feeding induced mitochondrial copper accumulation in LPP rats and therefore 
possibly caused the pronounced mitochondrial deficits in WD-fed Atp7b-/- rats. In 
agreement, it has been reported that mitochondrial impairments in Wilson disease 
are paralleled by elevated mitochondrial copper load and that mitochondrial  
de-coppering restores mitochondrial function [69]. However, the underlying 
 Discussion
P a g e  | 58 
molecular mechanisms how WD causes mitochondrial copper accumulation 
remain for further studies. 
4.8 Conclusions 
The present thesis demonstrated that WD causes mitochondrial molecular and 
functional adaptations. In mice, WD-caused steatosis was stable nearly 
life-long without establishing pronounced liver damage. This is highly similar to the 
human situation, as only a minority of NAFLD patients progress to the more 
severe liver disease state NASH. The present study further showed that 
WD-induced mitochondrial adaptations occur in parallel to steatosis and are a 
result of an altered mitochondrial membrane lipid composition but not a 
consequence of liver damage. These conclusions were substantiated by the 
findings that a decreased steatosis avoids fatty acid-induced mitochondrial deficits 
and that immune-deficient mice without any signs of liver damage presented WD-
caused mitochondrial adaptations as well. Finally, this study revealed WD-caused 
steatosis as semi-stable situation that might lead to severe liver damage by 
secondary liver insults, e.g. elevated calcium levels or enhanced mitochondrial 
copper load. 
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5. Summary
In western societies, NAFLD affects 20-40% of the general population and 
mitochondrial impairments have been frequently reported in humans with NAFLD 
and NASH. However, at which stage of the liver disease mitochondrial alterations 
occur and the molecular mechanisms that cause these alterations are still a matter 
of debate. Therefore, C57BL/6 mice were fed a high fat and fructose-containing 
western diet (WD), resembling the eating habits in western societies, and 
mitochondria were isolated after 6, 12, 24 and 48 weeks of feeding. To 
characterize the WD-induced mitochondrial alterations, the mitochondrial 
structure, proteome, lipidome and mitochondrial ATP and ROS production was 
determined.  
The underlying study demonstrates a progressive rise in obesity and liver steatosis 
due to prolonged WD feeding. However, cell death occurred only after 48 weeks of 
feeding. In contrast, mitochondrial alterations such as ballooned cristae, 
membrane fatty acid changes, alterations in membrane fluidity as well as 
decreased ATP production appeared already after 6 or 12 weeks of feeding. 
These fatty acid-caused mitochondrial alterations were dependent on the specific 
added fatty acid species. Moreover, mitochondrial impairments could be avoided 
by L-carnitine supplementation that decreased steatosis. These findings 
demonstrate that WD causes mitochondrial adaptations paralleled by steatosis, 
which were equally present in immune-deficient NLRP3-/- and IL-1R-/- mice and 
therefore are independent of NLRP3 inflammasome activation. Since these 
adaptations also appeared in IL-18R-/- mice that did not develop any liver damage, 
such adaptations are insufficient to cause pronounced hepatocyte death. 
Importantly, WD feeding sensitizes mitochondria to secondary liver insults, e.g. 
calcium or elevated mitochondrial copper-load in an animal model of Wilson 
disease. Thus, WD-caused steatosis is a semi-stable situation.  
In conclusion, the present thesis reveals important mechanisms how hepatocytes 
deal with and protect themselves against overwhelming saturated fatty acid supply 
in WD nutrition and highlights the mitochondrial flexibility due to dietary 
interventions.  
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7. Appendix
Abbreviations 
ADP Adenosine-5’-diphosphate 
ALiOS American Lifestyle-induced Obesity Syndrome 
ALT Alanine aminotransferase 
ANOVA Analysis of variance between groups 
ANT Adenine nucleotide translocator 
AST Aspartate aminotransferase 
ATP Adenosine-5’-triphosphate 
BSA Bovine serum albumin 
Ca Calcium 
CCCP Carbonyl cyanide m-chlorophenyl hydrazine 
CD-HFD Choline-deficient high fat diet 
CL Cardiolipin 
Cyt c Cytochrome c 
DAMP Damage-associated molecular pattern 
ER Endoplasmic reticulum 
ETC Electron transport chain  
FA Fatty acid 
FADH2 Flavin adenine dinucleotide 
FCCP Carbonyl cyanide-ρ-(trifluoromethoxy)phenylhydrazone 
H2O2 Hydrogen peroxide 
HCC Hepatocellular carcinoma 
HFD High fat diet 
HFLC High fat liver composition 
IM Inner mitochondrial membrane 
IMS Intermembrane space 
3-MA 3-Methyladenine 
MAM Mitochondrial-associated membranes 
MCD Methionine choline-deficient diet 
MHCII Major histocompartibility complex II 
MMP Mitochondrial membrane potential 
MOMP Mitochondrial outer membrane rupture 
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MPT Mitochondrial permeability transition 
mtDNA Mitochondrial desoxyribunucleic acid 
MUFA Monounsaturated fatty acid 
N2 Nitrogen 
NADH Nicotinamide adenine dinucleotide 
NAFLD Non-alcoholic fatty liver disease 
NASH Non-alcoholic steatohepatitis 
ND Normal diet 
NEFA Non-esterified fatty acids 
NFκB nuclear factor kappa-light-chain-enhancer of activated B cells 
O2 Oxygen 
OM Outer mitochondrial membrane 
PC Phosphatidylcholine 
PCC Pump controlled cell rupture system 
PE Phosphatidylethanolamine 
PEP Phosphoenolpyruvate 
Pi Inorganic phosphate 
PK Pyruvate kinase 
PUFA Polyunsaturated fatty acid 
RFU Relative fluorescence units 
ROS Reactive oxygen species 
RT Room temperature 
SFA Saturated fatty acid 
SLFC Standard liver fatty acid composition 
TG Triglyceride 
VDAC Voltage-dependent anion channel 
VLDL Very low density lipoprotein 
WD Western diet 
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6 weeks 
Protein Protein description Localization 
determined as regulated based on: 
Pathway p-
value 
CV                     
< 33% 
fold change >1.5, <0.67 
raw 
abundance 
normalized 
abundance 
ACOT13 acyl-CoA thioesterase 13 mitochondrion   1.75 1.77 lipid degradation 
ALDOB aldolase B, fructose-bisphosphate cytoplasm  Ѵ  1.64 miscellaneous 
ATP5D ATP synthase, H+ transporting, mitochondrial 
F1 complex, delta subunit 
mitochondrion  Ѵ 1.88 2.44 oxidative 
phosphorylation 
BHMT betaine-homocysteine methyltransferase cytoplasm  Ѵ  1.79 amino acid 
metabolism 
CALR calreticulin ER   1.62 1.84 ER stress 
CANX calnexin ER   1.65 2.05 ER stress 
CYP2A12 cytochrome P450, family 2, subfamily a, 
polypeptide 12 
ER   2.70 2.94 steroid 
metabolism 
EEF1A eukaryotic translation elongation factor 1 alpha 
1 
nucleus/ER   1.91 2.29 translation 
ELOVL2 elongation of very long chain fatty acids ER   2.41 2.87 lipid synthesis 
FMO5 flavin containing monooxygenase 5 ER   1.79 2.60 amino acid 
metabolism 
GM10036 predicted gene 10036 unknown   5.69 8.38 translation 
GM5619 predicted gene 5619 unknown   2.68 3.26 translation 
HADHB hydroxyacyl-Coenzyme A dehydrogenase/3-
ketoacyl-Coenzyme A thiolase/enoyl-
Coenzyme A hydratase (trifunctional protein), 
beta subunit  
mitochondrion 0.037   1.21 ß-oxidation/ 
amino acid 
metabolism 
HMGCS2 3-hydroxy-3-methylglutaryl-Coenzyme A 
synthase 2  
mitochondrion  Ѵ  1.56 lipid synthesis 
HSP90B1 heat shock protein 90, beta (Grp94), member 1 ER   1.88 2.08 ER stress 
HSPA5 heat shock protein 5 ER   1.74 1.80 ER stress 
METTL7a1 methyltransferase like 7A1 ER   1.69 2.15 miscellaneous 
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6 weeks 
Protein Protein description Localization 
determined as regulated based on: 
Pathway p-
value 
CV    
< 33% 
fold change >1.5, <0.67 
raw 
abundance 
normalized 
abundance 
MRPL10 mitochondrial ribosomal protein L10 mitochondrion Ѵ 1.55 translation 
MRPL43 mitochondrial ribosomal protein L43 mitochondrion 2.62 3.40 translation 
MRPS23 mitochondrial ribosomal protein S23 mitochondrion 1.64 2.07 translation 
MTTP microsomal triglyceride transfer protein ER 1.92 3.06 lipid transport 
OTUB1 OTU domain, ubiquitin aldehyde binding 1 cytoplasm 1.66 1.69 protein 
degradation 
P4HB prolyl 4-hydroxylase, beta polypeptide ER 0.027 Ѵ 1.87 2.59 ER stress 
PDIA6 protein disulfide isomerase associated 6 ER 0.024 Ѵ 1.92 2.56 ER stress 
PEX14 peroxisomal biogenesis factor 14 peroxisome 1.95 2.91 autophagy 
PGRMC1 progesterone receptor membrane component 1 ER 0.034 Ѵ 1.55 2.30 autophagy 
RPLP0 ribosomal protein, large, P0 ribosome/ER 1.58 1.85 translation 
RPLP2 ribosomal protein, large P2 ribosome/ER 2.90 3.02 translation 
RPN2 ribophorin II ribosome/ER 1.87 1.99 translation 
RPS3 ribosomal protein S3 ribosome/ER 3.59 4.42 miscellaneous 
SLC27A5 olute carrier family 27 (fatty acid transporter), 
member 5  
ER 1.59 1.73 lipid transport 
SOD1 superoxide dismutase 1, soluble cytoplasm Ѵ 1.54 antioxidative 
SURF4 surfeit gene 4 ER/Golgi 2.61 2.09 miscellaneous 
TECR trans-2,3-enoyl-CoA reductase ER 2.15 3.19 lipid synthesis 
TMEM205 transmembrane protein 205 membrane 2.16 2.32 miscellaneous 
UGT1A1 UDP glucuronosyltransferase 1 family, 
polypeptide A1  
ER 1.66 2.07 miscellaneous 
VKORC1 vitamin K epoxide reductase complex, subunit 1 ER 4.00 4.08 miscellaneous 
ACOX2 acyl-Coenzyme A oxidase 2, branched chain peroxisome 0.55 0.60 ß-oxidation 
CREG1 cellular repressor of E1A-stimulated genes 1 unknown 0.24 0.28 autophagy 
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6 weeks 
Protein Protein description Localization 
determined as regulated based on: 
Pathway p-
value 
CV                     
< 33% 
fold change >1.5, <0.67 
raw 
abundance 
normalized 
abundance 
CTSB cathepsin B  lysosome  Ѵ 0.39 0.44 lysosomal 
degradation 
DHRS1 dehydrogenase/reductase (SDR family) 
member 1 
mitochondrion   0.53 0.61 steroid 
metabolism 
ETHE1 ethylmalonic encephalopathy 1 mitochondrion   0.47 0.52 amino acid 
metabolism 
GPX1 glutathione peroxidase 1  cytoplasm  Ѵ  0.67 antioxidative 
LGMN legumain lysosome   0.42 0.37 lysosomal 
degradation 
LIPA lysosomal acid lipase A lysosome   0.22 0.23 lipid degradation 
LYPLA1 lysophospholipase 1 cytoplasm   0.62 0.66 lipid degradation 
MCU mitochondrial calcium uniporter mitochondrion   0.48 0.57 miscellaneous 
NAGS N-acetylglutamate synthase mitochondrion   0.38 0.40 amino acid 
metabolism 
NIT1 nitrilase 1 mitochondrion  Ѵ  0.61 apoptosis 
PHYH phytanoyl-CoA hydroxylase peroxisome   0.47 0.50 lipid degradation 
SCPEP1 serine carboxypeptidase 1 unknown   0.25 0.31 protein 
degradation 
STRA6 stimulated by retinoic acid gene 6 membrane   0.42 0.59 retinol 
metabolism 
TPP1 tripeptidyl peptidase I lysosome   0.47 0.55 lysosomal 
degradation 
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12 weeks 
Protein Protein description Localization 
determined as regulated based on: 
Pathway p-
value 
CV                     
< 33% 
fold change >1.5, <0.67 
raw 
abundance 
normalized 
abundance 
1110001J03
Rik 
RIKEN cDNA 1110001J03 gene, FMC1 
(mitochondrial complex I homolog) 
unknown   1.62 1.89 miscellaneous 
DAP3 death associated protein 3  mitochondrion 0.042 Ѵ  2.33 apoptosis 
ECHS1 enoyl Coenzyme A hydratase, short chain, 1, mitochondrion 0.030   1.17 lipid degradation 
ECI2 enoyl-Coenzyme A delta isomerase 2 mitochondrion 0.031   1.05 lipid degradation 
H2-Q10 histocompatibility 2, Q region locus 10 membrane   2.04 2.59 miscellaneous 
HSPE1 heat shock protein 1 (chaperonin 10) mitochondrion 0.024   1.15 miscellaneous 
MCAT malonyl CoA:ACP acyltransferase  mitochondrion   1.60 1.83 lipid transport 
MT-CO3 mitochondrially encoded cytochrome c  
oxidase III 
mitochondrion   1.78 1.75 oxidative 
phosphorylation 
RPL26 ribosomal protein L26 ER   2.05 1.82 translation 
RPL9 ribosomal protein L9  ribosome  Ѵ  1.53 translation 
SELO selenoprotein O unknown   1.83 1.77 miscellaneous 
ATL2 atlastin GTPase 2 ER   0.39 0.67 miscellaneous 
BNIP3 BCL2/adenovirus E1B interacting protein 3 mitochondrion   0.45 0.61 autophagy 
CREG1 cellular repressor of E1A-stimulated genes 1 unknown   0.45 0.59 autophagy 
CTSB cathepsin B  lysosome   0.49 0.60 lysosomal 
degradation 
CYP2A5 cytochrome P450, family 2, subfamily a, 
polypeptide 5  
unknown   0.27 0.48 retinol 
metabolism 
CYP2D9 cytochrome P450, family 2, subfamily d, 
polypeptide 9 
ER   0.28 0.52 retinol 
metabolism 
CYP3A16 cytochrome P450, family 3, subfamily a, 
polypeptide 16 
ER   0.31 0.56 steroid 
metabolism 
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12 weeks 
Protein Protein description Localization 
determined as regulated based on: 
Pathway p-
value 
CV                     
< 33% 
fold change >1.5, <0.67 
raw 
abundance 
normalized 
abundance 
DHRS1 dehydrogenase/reductase (SDR family) 
member 1 
mitochondrion   0.56 0.62 steroid 
metabolism 
FMO1 flavin containing monooxygenase 1 ER   0.13 0.31 amino acid 
metabolism 
GAA glucosidase, alpha, acid lysosome   0.35 0.49 lysosomal 
degradation 
GM2A GM2 ganglioside activator protein lysosome   0.32 0.47 lysosomal 
degradation 
GNMT glycine N-methyltransferase  cytoplasm   0.30 0.42 amino acid 
metabolism 
GSTA3 glutathione S-transferase, alpha 3 cytoplasm   0.50 0.59 antioxidative 
GSTM1 glutathione S-transferase, mu 1 cytoplasm   0.33 0.29 antioxidative 
GSTZ1 glutathione transferase zeta 1  cytoplasm 0.044 Ѵ 0.61 0.63 antioxidative 
ISCU IscU iron-sulfur cluster scaffold homolog mitochondrion   0.52 0.63 miscellaneous 
MRRF mitochondrial ribosome recycling factor mitochondrion   0.66 0.65 translation 
MT-ND4 mitochondrially encoded NADH 
dehydrogenase 4 
mitochondrion   0.43 0.43 oxidative 
phosphorylation 
NAGS N-acetylglutamate synthase mitochondrion   0.49 0.65 amino acid 
metabolism 
PEX14 peroxisomal biogenesis factor 14 peroxisome   0.44 0.48 autophagy 
PTGES2 prostaglandin E synthase 2 cytoplasm/Golgi   0.54 0.58 miscellaneous 
QDPR quinoid dihydropteridine reductase mitochondrion   0.30 0.30 amino acid 
metabolism 
RNASET2B ribonuclease T2B  ER   0.47 0.60 translation 
STRA6 stimulated by retinoic acid gene 6 membrane   0.15 0.23 retinol 
metabolism 
TMEM256 transmembrane protein 256 membrane  Ѵ  0.51 miscellaneous 
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12 weeks 
Protein Protein description Localization 
determined as regulated based on: 
Pathway p-
value 
CV                     
< 33% 
fold change >1.5, <0.67 
raw 
abundance 
normalized 
abundance 
TTR transthyretin unknown   0.48 0.58 retinol 
metabolism 
UQCR11 ubiquinol-cytochrome c reductase, complex III 
subunit XI 
mitochondrion   0.63 0.56 oxidative 
phosphorylation 
24 weeks        
ACOT2 acyl-CoA thioesterase 2  mitochondrion   1.92 2.05 lipid degradation 
AMT aminomethyltransferase mitochondrion   1.57 1.60 amino acid 
metabolism 
ATL2 atlastin GTPase 2 ER   2.83 7.35 miscellaneous 
BDH1 3-hydroxybutyrate dehydrogenase, type 1 mitochondrion  Ѵ  1.58 miscellaneous 
CYP2D9 cytochrome P450, family 2, subfamily d, 
polypeptide 9 
ER   1.88 1.91 lipid degradation 
ECHDC2 enoyl Coenzyme A hydratase domain 
containing 2 
mitochondrion 0.034 Ѵ  1.79 lipid synthesis 
EHHADH enoyl-Coenzyme A, hydratase/3-hydroxyacyl 
Coenzyme A dehydrogenase 
peroxisome 0.018 Ѵ  1.82 lipid degradation 
ELOVL2 elongation of very long chain fatty acids ER   4.99 3.75 lipid synthesis 
GM10036 predicted gene 10036 unknown   1.66 1.67 translation 
HADHA hydroxyacyl-Coenzyme A dehydrogenase/3-
ketoacyl-Coenzyme A thiolase/enoyl-
Coenzyme A hydratase (trifunctional protein), 
alpha subunit  
mitochondrion 0.018 Ѵ  1.56 lipid degradation 
HMGCS2 3-hydroxy-3-methylglutaryl-Coenzyme A 
synthase 2 
mitochondrion 0.031 Ѵ  1.69 lipid synthesis 
MCU mitochondrial calcium uniporter mitochondrion   1.48 1.63 miscellaneous 
MRPS30 mitochondrial ribosomal protein S30 mitochondrion  Ѵ 1.45 2.14 translation 
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24 weeks 
Protein Protein description Localization 
determined as regulated based on: 
Pathway p-
value 
CV                     
< 33% 
fold change >1.5, <0.67 
raw 
abundance 
normalized 
abundance 
MTHFS 5, 10-methenyltetrahydrofolate synthetase cytoplasm   1.96 2.51 miscellaneous 
MT-ND5 mitochondrially encoded NADH 
dehydrogenase 5 
mitochondrion   1.90 1.69 oxidative 
phosphorylation 
NDUFA11 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex 11 
membrane    Ѵ  1.73 oxidative 
phosphorylation 
NIT1 nitrilase 1 mitochondrion  Ѵ 1.40 1.90 apoptosis 
NNT nicotinamide nucleotide transhydrogenase mitochondrion 0.005 Ѵ  1.89 miscellaneous 
P4HB prolyl 4-hydroxylase, beta polypeptide ER 0.037 Ѵ  2.14 antioxidative 
PMPCA peptidase (mitochondrial processing) alpha mitochondrion   1.64 2.02 protein 
degradation 
RPL9 ribosomal protein L9 ribosome  Ѵ  1.55 translation 
SCD1 stearoyl-Coenzyme A desaturase 1 ER   1.56 1.69 lipid synthesis 
SCP2 sterol carrier protein 2 mitochondrion  Ѵ  1.79 lipid transport 
SSR4 signal sequence receptor, delta ER   1.15 1.64 miscellaneous 
STRA6 stimulated by retinoic acid gene 6  membrane   1.88 3.32 retinol 
metabolism 
SURF4 surfeit gene 4 ER/Golgi   1.38 3.72 miscellaneous 
UGT2B36 UDP glucuronosyltransferase 2 family, 
polypeptide B36 
unknown 0.029  1.54 3.33 steroid 
metabolism 
ALDH1B1 aldehyde dehydrogenase 1 family, member B1 mitochondrion  Ѵ  0.62 steroid 
metabolism 
CTSB cathepsin B  lysosome   0.43 0.46 lysosomal 
degradation 
CYP2A5 cytochrome P450, family 2, subfamily a, 
polypeptide 5 
unknown 0.041  0.28 0.29 retinol 
metabolism 
CYP3A16 cytochrome P450, family 3, subfamily a, 
polypeptide 16 
ER   0.14 0.25 steroid 
metabolism 
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24 weeks 
Protein Protein description Localization 
determined as regulated based on: 
Pathway p-
value 
CV    
< 33% 
fold change >1.5, <0.67 
raw 
abundance 
normalized 
abundance 
ETHE1 ethylmalonic encephalopathy 1 mitochondrion 0.42 0.35 amino acid 
metabolism 
FBXO16 F-box protein 16 unknown 0.019 0.39 0.44 protein 
degradation 
GAA glucosidase, alpha, acid lysosome 0.38 0.58 lysosomal 
degradation 
GNMT glycine N-methyltransferase cytoplasm 0.23 0.30 amino acid 
metabolism 
LIPA lysosomal acid lipase A lysosome 0.29 0.32 lipid degradation 
MUP10 major urinary protein 10 unknown 0.42 0.57 miscellaneous 
OTC ornithine transcarbamylase mitochondrion 0.025 0.73 miscellaneous 
PHYH phytanoyl-CoA hydroxylase peroxisome 0.41 0.41 lipid degradation 
SARDH sarcosine dehydrogenase mitochondrion 0.047 Ѵ 0.66 amino acid 
metabolism 
SCPEP1 serine carboxypeptidase 1 unknown 0.40 0.56 protein 
degradation 
SARDH sarcosine dehydrogenase mitochondrion 0.047 Ѵ 0.66 amino acid 
metabolism 
SCPEP1 serine carboxypeptidase 1 unknown 0.40 0.56 protein 
degradation 
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